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INTRODUCTION 
 
AML- EPIDEMIOLOGY AND ETIOLOGY 
 
   Acute myeloid leukemia (AML) is the most common myeloid malignancy; the median age at the time 
of diagnosis is 70 years and men have a slightly higher incidence (ratio 3:2) [1]. The etiology of the 
disease can be identified only for a minority of patients, even though several risk factors are known. 
Firstly, exposure to ionizing radiation increases the risk of cancer in general and especially of myeloid 
malignancies; this has been studied in detail among survivors of the atomic bombs in Japan at the end 
of the Second World War [2]. Radiation is probably also the cause of an increased incidence among 
cockpit crew [3]. Secondly, exposure to environment toxins is associated with AML; occupational 
benzene exposure is well established as a risk factor [4], and the benzene content in cigarette smoke 
may also explain the slight increase in AML incidence among smokers [5]. Thirdly, treatment of other 
malignancies with chemotherapy and/or radiotherapy increases the risk of a second malignancies, 
especially AML or myelodysplastic syndromes (MDS). Approximately 10-15% of AML cases are 
reported to be therapy related [6], and especially treatment with topoisomerase II inhibitors (e.g. 
doxorubicin, mitoxantrone and etoposide) and alkylating agents (e.g. cyklophosphamides and its 
derivates) seems to have a leukemogenic effect [6]. Finally, inherited genetic abnormalities (e.g. 
Downs syndrome, Li-Fraumeni syndrome, certain forms of congenital neutropenia) also increase the 
risk of AML.  
 
CLINICAL PRESENTATION OF AML 
 
   The clinical signs and symptoms of AML are diverse and nonspecific, they are usually caused by the 
leukemic bone marrow infiltration or more seldom by infiltration in other organs. The leukemic cell 
population blocks normal hematopoiesis and thereby causes cytopenia. This will usually affect all 
three myeloid lineages and cause anemia leading to fatigue, neutropenia causing infections and 
thrombocytopenia causing hemorrhages. Leukemic infiltration of other organs is less common and can 
manifest as hepatospelenomegaly, lymphadenopathy, gingival hyperplasia or central nervous system 
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(CNS) symptoms. Hyperleukocytosis with leukostatsis can lead to acute multiorgan failure. 
Exceptional patients present as a myeloid sarcoma, i.e. a single extra medullar mass of leukemic cells. 
 
 
DIAGNOSIS AND CLASSIFICATION OF AML 
 
   Although new diagnostic tools have been introduced during the last decades, the primary diagnosis 
of AML still rests on the morphological identification of leukemic blast in blood and/or bone marrow 
smears for most patients. These smears are examined after May-Grünwald-Giemsa or Wright-Giemsa 
staining. Bone marrow biopsy is not considered necessary for the diagnosis, but should be considered 
in patients with dry tap (punctio sicca). Leukemic blasts typical have a round-to-irregular nucleus, 
distinct nucleoli and very little fine granular cytoplasm. Auer rods could be seen in some cases. The 
diagnosis of acute leukemia requires the presence of >20% leukemic blast in the bone marrow, but for 
certain subtypes (e.g. t(8;21), t(16;16), inv(16;16)) this is not required [7]. The WHO criteria reduced 
the blast criteria from 30% in the FAB (French-American-British) classification to 20%, even though 
several investigators have argued that there may be a biological difference between patients with 20-
30% and more than 30% myeloblasts in the bone marrow at the time of diagnosis [8]. 
   The first subclassification in AML was the FAB-system based on leukemic cell morphology and 
histochemistry (Table 1). This system did not define prognostically relevant subsets except for the 
acute promyelocytic leukemia (APL) variant [9]. Morphological characteristics are still important in the 
more recent and generally accepted WHO classification (Table 2) [8], but this classification is in 
addition based on clinical characteristics (previous MDS or therapy related AML) and genetic 
abnormalities as will be described below (Table 2). 
 
Table 1. The FAB classification based on AML cell morphology [1, 10]. 
Classification Characteristics 
M0 Immature blasts without signs of differentiation 
M1 Without maturation 
M2 Evidence of granulocyte differentiation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia 
M5 Acute monocytic leukemia 
M6 Acute erythroleukemia 
M7 Acute megakaryoblastic leukemia 
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Table 2. The WHO classification of AML [1, 8, 11]; a classification based on clinical, 
morphological and genetic abnormalities.  
 
 Acute myeloid leukemia with recurrent genetic abnormalities  
     AML with t(8;21) 
     AML with inv(16) or t(16;16) 
     APL with t(15;17) 
     AML with t(9;11) 
     AML with t(6;9) 
     AML with inv(3) or t(3;3) 
     AML (megakaryoblastic) with t(1;22) 
     AML with mutated NPM1  
     AML with mutated CEBPA  
 
 Acute myeloid leukemia with myelodysplasia-related changes 
 
 Therapy-related myeloid neoplasms 
 
 Acute myeloid leukemia, not otherwise specified 
     AML with minimal differentiation  
     AML without maturation  
     AML with maturation  
     Acute myelomonocytic leukemia  
     Acute monoblastic/monocytic leukemia  
     Acute erythroid leukemia  
     Acute megakaryoblastic leukemia  
     Acute basophilic leukemia  
     Acute panmyelosis with myelofibrosis  
 
 Myeloid sarcoma   
 
 Myeloid proliferations related to Down syndrome  
     Transient abnormal myelopoiesis  
     Myeloid leukemia associated with Down syndrome  
 
 Blastic plasmacytoid dendritic cell neoplasm  
 
 Acute leukemias of ambiguous lineage  
     Acute undifferentiated leukemia  
     Mixed phenotype acute leukemia with t(9;22) 
     Mixed phenotype acute leukemia with t(v;11q23) 
     Mixed phenotype acute leukemia, B/myeloid 
     Mixed phenotype acute leukemia, T/myeloid 
 
 
   Immunophenotyping is mandatory to distinguish between AML and acute lymphoblastic leukemia 
(ALL) [12]. Especially expression of the CD34 stem cell marker is important [13]; it represents an 
additional independent prognostic factor and differences in CD34 expression are associated with 
distinct gene expression profiles [14]. Conventional cytogenetic analysis is a mandatory screening 
strategy for detection of genetic abnormalities; at least 20 metaphases should be analyzed and 
abnormalities are then detected in approximately 55% of the patients. An alternative to conventional 
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cytogenetic analysis for detection of specific gene rearrangement is fluorescence in situ hybridization 
(FISH). Finally, molecular analyses should be used to detect specific mutations.  
 
CYTOGENETIC ANALYSIS IN HUMAN AML 
 
   Cytogenetic abnormalities are found in approximately 55% of AML patients [11, 15-17], and the 
karyotype is one of the most powerful independent prognostic parameters in AML [17]. Loss or gain of 
chromosomes occurs due to unequal segregation of the chromosomes. The first translocation 
discovered in AML was the balanced translocation between chromosome 8 and 21; t(8;21) [18], and 
this genotype has distinct biological and clinical characteristics [7]. AML with t(8;21) or the 
t(16;16)/iv(16) have common characteristics and are often referred to as core binding factor (CBF)-
AML. CBF-AML together with the APL variant characterized by t(15;17) have a favorable prognosis. 
On the other hand, an adverse outcome is especially seen with (i) two or more distinct autosomal 
chromosome monosomies, (ii) one single autosomal monosomy in the presence of structural 
abnormalities (referred to as monsomal karyotype) [19], and (iii) complex karyotype with at least three 
abnormalities [16]. It should also be emphasized that many patients have rare cytogenetic 
abnormalities, and the prognostic impact of such abnormalities is often uncertain [16]. A classification 
of cytogenetic abnormalities according to their prognostic impact is given in Table 3 [11]. 
 
Table 3. Karyotype and prognosis [11]. 
  
Favorable abnormalities 
     t(15;17), t(8,21), inv(16)/t(16;16) 
 
 Intermediate  
    Normal cytogenetics 
    Entities not classified as favorable or adverse  
 
 Adverse  
     abn(3q), inv(3) 
     add(5q), del(5q), –5,  
     –7, add(7q)/del(7q) 
     +8 
     t(6;11), t(10;11) 
     t(11q23) (excluding t(9;11) and t(11;19) 
     t(9;22) 
     –17/abn(17p) 
     Multiple (>3 abnormalities) 
     Monosomal karyotype 
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MOLECULAR GENETICS OF HUMAN AML 
 
   Gene mutation and deregulated gene expression allow the description of the genetic diversity within 
defined cytogenetic groups [20, 21]. This is of particular importance for the large group (45%) with 
normal cytogenetics [15]. Cytogenetic and molecular genetic abnormalities are not mutually exclusive 
and often coexist. The mutations can broadly be divided into class I and class II mutation. Class I 
comprises mutations that activate signal transduction pathways and therefore increase survival and 
proliferation of the affected cells. In contrast, class II mutations interfere with transcription factors that 
are important for hematopoietic cell differentiation. Table 4 summarized the most common 
cytogenetics and molecular genetics aberration in the two classes. 
 
Table 4. Genes involved in class I and class II AML-associated mutations  
Class I mutations Class II mutations 
 
FLT3-ITD 
 
PML-RARA/t(15;17) 
FLT3-TKD AML-ETO/t(8;21) 
KIT CBFB-MYH11/inv(16)-t(16;16) 
JAK NPM1 
NRAS CEBPA 
KRAS MLL 
 RUNX1/AML 
 
    
 
The "second hit" hypothesis is based on this classification, postulating that one class I mutation and 
one class II mutation are necessary for transformation to the complete malignant phenotype. Although 
this theory does not fit all AML cases, it can explain why a type I mutation often coexist with a type II 
mutation, e.g. KIT and AML-ETO [7] and FLT3-ITD and NPM1 [15]. The most important mutations will 
be described below and their characteristics are briefly summarized in Table 5. 
   
ASXL1 mutations 
The Additional Sex Comb-Like 1 (ASXL1) gene on chromosome 20q11.1 encodes a protein believed 
to be involved in chromatin modification and to act as a coactivator for the retinoic acid receptor [22]. 
The mutations occur in exon 12, with a frequency in AML probably between 5 and 10 % [22, 23]. The 
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mutation is associated with older age, male sex and secondary AML [22, 23].  The prognostic impact 
is negative, with inferior complete remission rates [23], and shorter overall survival [22]. 
 
BAALC expression level 
   The Brain And Acute Leukemia, Cytoplasmatic (BAALC) gene is located on chromosome band 8q23 
[24]. The function of the BAALC protein is largely unknown, it is highly expressed in hematopoietic 
precursor cells as well as leukemic blasts and is down-regulated during differentiation [24]. High 
BAALC expression is a poor prognostic parameter in cytogenetically normal AML [24, 25]. 
 
CEBPA mutations 
   The transcription factor CCAAT enhancer binding protein alpha (CEBPA) is crucial for normal 
differentiation of granulocytes [26]. The two most important mutations are N-terminal frame-shift 
mutations and C-terminal in-frame insertions, and together they are observed in roughly 10% of AML 
patients either in the combination on separate alleles (CEBPAdouble-mut) or as single mutation 
(CEBPAsingle-mut). These patients are often classified as FAB subtype M1 or M2 and have normal 
cytogenetics.  Patient with CEBPAdouble-mut seem to have a distinct gene expression profile [27-29], and 
a more favorable prognosis than patients with CEBPAsingle-mut [28, 29]. Both the gene expression profile 
and the favorable prognostic impact of CEBPAdouble-mut indicate that this AML subset is related to the 
CBF-AMLs [29].  Analysis of CEBPA mutational status has recently been suggested as a part of the 
routine clinical handling of AML patients [11]. 
 
DNMT3A mutations 
   A recent study described mutations in DNA methyltransferase 3A (DNMT3A) in 22% of AML patients 
[30]. This was confirmed in two recent studies, reporting a frequence of DNMT3A mutations of 18% 
[31, 32]. The mutation was absent in APL (t15;17) and CBF-AML, but had an increased frequency in 
patients with intermediate-risk cytogenetics [30]. The mutation seems to be associated with monocytic 
features [33] and seems to have an adverse prognostic impact [30-33].  
 
 
 
17
ERG expression level 
   The ETS-related gene (ERG) is located at chromosome band 21p22 and is involved in regulation of 
proliferation, apoptosis and differentiation [34, 35]. High ERG expression in AML is associated with 
upregulation of genes involved in leukemogenesis [34]. Cytogenetically normal AML with high ERG 
expression has decreased remission rate, higher relapse rate and reduced overall survival [34, 35]. 
The adverse prognostic impact of high ERG expression is seen especially in patients with NPM1 
mutation and normal cytogenetic [35].  
 
FLT3 abnormalities 
   The FLT3 gene is localized on chromosome 13q12 and encodes a receptor tyrosine kinase (RTK) 
with an extracellular ligand-binding part and an intracellular catalytic unit [36].  FLT3 ligation leads to 
complex protein interactions by the intracellular domain [36] that induces a cascade of protein 
phosphorylation events in downstream targets including mitogen-activated protein (MAP) kinase, 
signal transducer and activator (STAT) molecules, phosphatidylinositol 3-kinase (PI3K) and AKT. 
FLT3 interacts with several other cytokines including stem cell factor (SCF), interleukin-3 (IL-3) and 
granulocyte macrophage colony stimulating factor (GM-CSF) in the regulation of phospholipid 
metabolism, gene transcription, proliferation and apoptosis of hematopoietic cells. 
   The most important AML-associated abnormalities of the FLT3 gene are the in frame internal 
tandem duplications (FLT3-ITD) [37]. These mutations consist of insertions of variable length in the 
juxtamedullar encoding part of the gene [38], they occur in approximately 25% of the patients [39] and 
in approximately 30% of patients with normal cytogenetics [40]. FLT3-ITD is associated with an 
adverse prognosis [39, 40], although this prognostic impact seems to depend on the size of the ITD 
[38]. Analysis of the FLT3 mutational status is regarded as mandatory in the clinical handling of AML 
patients [11]. 
   The second type of FLT3 mutations is missense point mutations in the tyrosine kinase domain 
(TKD), most of them occurring in codon 835 and therefore referred to as D835 mutation. This mutation 
occurs in approximately 5 % of patients [15]. Although both FLT3-ITD and FLT3-TKD mutations cause 
constitutive receptor activation, they seem to differ in their downstream signaling events [41] and this 
is possibly the reason why they do not cluster together in gene expression analyses [20] and differ in 
their prognostic impact. While FLT3-ITD clearly is associated with a more unfavorable outcome, the 
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role of FLT3-TKD is controversial. This may have been confounded by the fact that FLT3-TKD often 
coexist with other mutations, especially the favorable NPM1 mutation [42], whereas patients with 
FLT3-TKD as the sole abnormality may have a poor outcome [40]. 
 
IDH mutations 
   The IDH1 and IDH2 genes encode two isoforms of isocitrate dehydrogenase (IDH); mutation of this 
gene was first detected by DNA sequencing of the whole genome of an AML patient [43], and the 
mutations were thereafter identified in 15 out of 187 patients [44]. Three later studies [45-47] 
demonstrated that the frequencies of IDH1 and IDH2 mutations were 7.6-9.6% and 3.0-7.0% 
respectively [46, 47]. Both IDH1 (14% of these patients) and IDH2 (19%) mutations are more frequent 
in patients with normal cytogenetics [45], and IDH1 mutations were in addition associated with NPM1 
mutation [46, 47]. All these studies reported an adverse prognostic impact by both mutations [45-47]. 
 
JAK mutations 
   The janus kinase (JAK) genes encode non-receptor thyrosine kinases that can be divided in the four 
families JAK1, JAK2, JAK3 and TYK2 [48, 49]. These enzymes are important for activation of STAT 
molecules that are involved in both normal and leukemic hematopoiesis. The acquired JAK2 V617F 
mutation is frequently found in myeloproliferative neoplasms, especially polycythemia vera (PV). JAK 1 
and JAK2 mutations are relatively uncommon and especially detected in AML secondary to 
myeloproliferative neoplasms [48, 49], whereas JAK3 mutations are detected especially in the rare 
variant acute megakaryoblastic leukemia (M7) [50]. The prognostic impact of these mutations is not 
completely known.    
 
KIT mutations 
   The KIT-encoding gene is located at chromosome band 4q11 [51, 52]. KIT mutations are observed 
in approximately 30% of CBF-AML [7, 51, 52], the mutations may then have an adverse prognostic 
impact [52] and seem to be associated with a distinct gene expression signature and deregulation of 
the nuclear factor țB  (NF-țB) pathway [53]. Specific small-molecule tyrosine kinase inhibitors (TKIs) 
are considered for the treatment of these patients [54].  
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RAS mutations 
   RAS oncogenes (N-RAS, K-RAS and H-RAS) encode a family of membrane-associated proteins 
that regulate signal transduction and are involved in regulation of proliferation, differentiation and 
apoptosis [55]. Mutations of RAS genes are predominantly found in codons 12, 13 and 61, and they 
lead to constitutive activity of the RAS proteins with uncontrolled proliferation and antiapoptotic 
signaling. Mutations in N-RAS are most frequent and appear in 10-15% of AML patients [15, 55-57], K-
RAS mutation occurs in approximately 5% of patients [55] whereas mutated H-RAS is uncommon [55]. 
Both N-RAS and K-RAS can be associated with inv(16)/t(16;16) [56] and probably represent a “second 
hit” (see above). RAS mutations do not seem to have any prognostic impact in patients receiving 
intensive chemotherapy [56, 57]. 
 
MLL mutations 
   Molecular studies of the breakpoint regions of several translocations involving chromosomal band 
11q23 identified the Mixed-Lineage Leukemia (MLL) gene [58]. This gene is also called HRX or ALL-1. 
The MLL protein is a part of a large molecular complex involved in nucleosomal remodeling and 
histone deacetylation and methylation [58]. MLL mutations occur in approximately 5% of AML cases 
[58], the frequency being slightly higher in cytogenetically normal AML (7%) [15], and in secondary 
and therapy-related AML [58]. MLL mutations are considered as an adverse prognostic parameter with 
reduced remission rates [59]. MLL is a stable genetic marker and may become useful for detection of 
minimal residual disease (MRD) in human AML [60]. 
 
MN1 expression level  
   The meningioma 1 (MN1) gene is located at chromosome band 22q11 [61, 62], and encodes a 
protein involved in transcriptional regulation. Overexpression of MN1 is often observed together with 
NPM1 wild-type and BAALC overexpression [61], high expression is associated with low remission 
rate and it is an independent adverse prognostic factor [61, 62]. 
 
NPM1 mutations 
   Nucleophosmin1 (NPM1) is a chaperone protein that shuttles between the nucleus and cytoplasm; it 
predominantly resides in the nucleolus and is involved in the regulation of multiple cellular functions 
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that possess both oncogenic and tumor-suppressor properties [63]. In 2005 somatic mutations in exon 
12 of the NPM1 encoding gene were described; this abnormality leads to aberrant localization of the 
NPM1 protein in the cytoplasm, thus the designation NPMc+ AML [64]. NPMc+ AML is also 
characterized by unique global gene expression and microRNA signatures [65, 66]. 
   NPM1 mutations are found in approximately 30-35% of all AML cases and up to 60% of patients with 
normal cytogenetics [64]. Patients with NPM1 mutations are twice as likely to have FLT3-ITD 
mutations as those without this abnormality [64], and NPMc+ AML is associated with a favorable 
prognosis in the absence of a coexisting FLT3-ITD [11, 64]. 
 
RUNX1/AML1 mutations 
   Runt-related transcription factor 1 (RUNX1, also called AML1) was initially identified from the 
breakpoint region of t(8;21) AML [7]. The encoded protein represents the alpha subunit of CBF and is 
involved in normal hematopoiesis. Chromosomal translocations involving this gene are well-
documented in human leukemia [7]. In addition to translocations, specific mutations in the RUNX1 
gene occur in approximately 5% of AML cases [67], and are probably most common in secondary 
AML [67, 68]. Although an initial study indicated inferior outcoume for patients with RUNX1 mutations 
[67], the total prognostic impact of these mutations remains to be established. 
 
TET2 mutations 
  Mutations of the tet oncogene family member 2 (TET2) gene were recently described in different 
hematological malignancies [69]. The mutations are heterogeneous [69] and are detected in 8-24% of 
AML patients [69-71]. The biological effects and the prognostic impact of these mutations have to be 
further evaluated, but the first reports described no significant prognostic impact [71].  
 
TP53 mutations 
   p53 is important in coordinating cellular responses to a wide range of stress factors. Inactivation of 
p53 through mutations in the tumor protein 53 (TP53)-encoding gene on chromosome 17p is detected 
in more than 50% of solid tumors [72]. However, p53 mutations are uncommon in hematologic 
malignancies and found only in approximately 5% of AML patients [73]. TP53 mutations in AML are 
associated with complex cytogenetic abnormalities, chemoresistance, high relapse rate and adverse 
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prognosis [73, 74]. Single TP53 deletion should therefore be regarded as high-risk aberrations in AML 
[73, 74]. 
 
WT1 mutations 
   The Wilms Tumor 1 (WT1) gene is located on chromosome 11p13, and mutated WT1 gene was first 
described in AML more than a decade ago [75]. WT1 is probably important in regulation of survival, 
proliferation and differentiation of hematopoietic cells [76]. The mutations occur in approximately 10% 
of adult patients and are most frequent in patients with normal cytogenetics [76]. The first report 
suggested an adverse prognostic impact [75], and this has later been confirmed [77, 78]. 
 
 
Table 5. A summary of the most common molecular genetic abnormalities in human AML. 
GENE DEFECT APPROXIMATE OCCURRENCE PROGNOSTIC IMPACT 
ASXL1 Mutation 5-10% Adverse 
BAALC Overexpression - Adverse 
CEBPA Double mutation 10% Favorable 
DNMT3A Mutation 20% Adverse 
ERG Overexpression - Adverse 
FLT3 ITD-mutation 25-30% Adverse 
FLT3 TKD-mutation 5% Adverse 
IDH1/2 Mutation 10% Adverse 
JAK Mutation 5% Intermediate 
KIT Mutation 10% Adverse in CBF-AML 
K-RAS Mutation 5% Intermediate 
MLL Mutation 5% Adverse 
MN1 Overexpression - Adverse 
NPM1 Insertion 30-35% Favorable without FLT3-ITD 
N-RAS Mutation 10-15% Intermediate 
RUNX1/AML1 Mutation 5-10% Intermediate 
TET2 Mutation 10% Intermediate 
TP53 Mutation 5% Adverse 
WT1 Frame shift mutation 10% Adverse 
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CONVENTIONAL TREATMENT OF AML 
 
   The primary objective for the intensive chemotherapy in AML is to induce remission (disease control) 
through the induction treatment and thereafter to prevent relapse from residual disease (consolidation 
therapy). The aim of induction therapy is thus to reduce the leukemia cell burden and reach complete 
hematological remission, i.e. <5% blasts in the bone marrow with absence of Auer rods and 
extramedullary disease, restoration of normal hematopoiesis with peripheral blood  platelet count >100 
x 109/l,  neutrophil count >1,0 x 109/l and independence or red cell transfusions [11].   
   An antracycline, usually daunorubicin, combined with cytarabine is the cornerstone in the induction 
treatment. Antracycline is given for three days [11], while cytarabine is given as continuous infusion for 
seven days (100-200 mg/m2/day), e.g. the 3+7 regimen. Antracyclines work both by inhibiting DNA 
synthesis and causing DNA damage, and one important side effect is their cardiotoxicity. Cytarabine is 
an antimetabolite that causes DNA damage and thereby triggering of programmed cell death. High-
dose cytarabine in the induction regimen results in excessive toxicity without further therapeutic benefit 
[79]. Other antracyclines than daunorubicin have been evaluated but seem to be inferior when using 
equivalent doses [11, 80]. Attempts to improve patient outcome by using additional cytotoxic agents 
have also failed [80]. Finally, priming of the AML cells to cell-cycle specific agents through the 
administration of the hematopoietic growth factors G-CSF [81] or GM-CSF [82] has also been tried; 
some studies have reported promising results especially for subgroups of patients [81, 82], but this 
treatment is not recommended for routine clinical practice [11].  
   The consolidation therapy can be either conventional intensive chemotherapy or stem cell 
transplantation. Firstly, based on a large randomized clinical trial the standard treatment for younger 
patients has been based on highdose cytarabine (single doses 3 g/m2) for younger patients below 60 
years of age [83]. Secondly, autologous stem cell transplantation (auto-SCT) can also be included in 
the consolidation treatment. Finally, allogeneic stem cell transplantation (allo-SCT) is the most 
powerful antileukemic treatment. The stem cells from either a HLA-matched family or unrelated donor 
are transfused to the patient after initial intensive conditioning therapy. Antileukemic effects are then 
mediated both by the conditioning therapy and by immune-mediated graft-versus leukemia effects [1, 
11, 84, 85]. However, due to the risk of transplant-related mortality patients and donors have to be 
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carefully selected. A reduced-intensity conditioning (RIC) regimen may offer an advantage for subsets 
of patients with increased risk of severe transplant-related complications, e.g. elderly patients [86]. 
   Risk stratification is now used as a basis for deciding the consolidation treatment, the most important 
factors in standardized risk assessments being the response to the first induction cycle together with 
the cytogenetic analysis and mutation status especially for NPM1 and FLT3 and possibly also KIT and 
CEBPA [87]. The level of circulating blast cells also seems to be important at least in certain subsets 
of patients [88]. An example of risk stratification is given in Table 6. 
 
Table 6. Risk assessment of patients with newly diagnosed AML based on cytogenetic analysis 
and selected gene mutations [11, 80, 87] (wt, wild type; + means mutated, double-mut means two 
mutated alleles). 
 
 
Risk of chemoresistance or 
AML relapse Cytogenetic analysis 
Cytogenetics combined with 
molecular genetic analysis 
 
Favorable prognosis 
 
t(8;21) 
inv(16)/t(16;16) 
t(15;17) 
 
 
Normal cytogenetics plus: 
-  NPM1+ and FLT3-wt 
- CEBPAdouble-mut  and FLT3-wt 
Intermediate prognosis Normal cytogenetics 
t(9;11), +8, t(3;5) 
Other cytogenetic abnormalities 
not classified as favorable or 
adverse 
 
KIT mutations  in the presence of 
t(8;21) or inv(16)/t(16;16) 
 
Adverse prognosis Specific abnormalities: 
Inv(3)/t(3;3), t(6;9), t(v;11),  
-5, 5q-, -7, 7q- 
abnl(17p) 
Monosomal or complex 
karyotype 
 
Intermediate risk cytogenetics plus 
FLT3-ITD+ 
 
 
 
   For patients below 60 years of age in the favorable risk group the consolidation therapy will often be 
repetitive cycles of high-dose cytarabine without auto-SCT or allo-SCT [89]. However, certain subsets 
of these patients seem to have an inferior prognosis, e.g. t(8;21) AML presenting with high levels of 
circulating blasts or possibly also with KIT mutations [52, 90]; allo-SCT may be considered for these 
patients [80, 87]. For the intermediate group consolidation therapy with high-dose cytarabine is still 
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widely used, but allo-SCT is regarded as superior especially for patient with low transplant risk (e.g. 
low age and no comorbidity) [91], and for patients harboring FLT3-ITD mutation [15, 92]. Finally, for 
the adverse group allo-SCT is superior to other regimen [89, 91]. Highdose cytarabine should here 
only be considered in the consolidation regime if it is impossible to find a matched related or unrelated 
donor, or if the risk of transplantation is considered too high [80]. 
 
 
SPECIAL SITUATIONS IN THE TREATMENT OF AML 
 
Relapsed AML 
   Leukemia relapse after achievement of complete remission is usually seen within three years after 
diagnosis. The possibility to achieve a second remission after intensive conventional induction therapy 
depends on the time in remission until relapse, age, cytogenetics and whether a previously allo-SCT 
has been preformed, but the only realistic possibility of cure is an allo-SCT [93]. Clinical studies of 
intensive chemotherapy are few and often relatively small, and the treatment is therefore often based 
on local traditions without any consensus. Intermediate or highdose cytarabine is often used, 
alternative regimen include mitoxantrone or etoposide [11]. Previously allotransplanted patients may 
be offered a retransplantation if they have a late relapse [94]. If allo-SCT is impossible an auto-SCT 
may be an alternative [11]. However, for a major part of these patients the best alternative will be 
optimal palliative or eventually disease-stabilizing treatment.  
 
AML secondary to previous chemotherapy or chronic myeloproliferative disease 
   AML can develop after earlier chemotherapy and/or radiotherapy, and these patients have an 
inferior outcome. Therapy-related AML is associated with high frequency of unfavorable cytogenetic 
abnormalities, the remission rate is relatively low and the risk of relapse is high [95]. According to the 
WHO classification the term secondary AML includes AML with myelodysplastic changes and AML 
developing after previous MDS or chronic myeloproliferative neoplasms. The incidence of secondary 
AML varies between different studies and it is associated with an adverse prognosis due to several 
factors, including high age, increased comorbidity and high frequencies of high-risk cytogenetic 
abnormalities. The treatment of secondary AML is in principle the same as for de novo AML, but these 
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patients are often more difficult to bring into remission, and further treatment should be carefully 
considered in the delicate balance between benefits and harms for the patient.  
 
Acute promyelocytic leukemia (APL) 
   APL (FAB classification M3) is a distinct subtype of AML that is characterized by accumulation of 
promyelocytes in the bone marrow, the presentation is often characterized by rapid progression and 
disseminated intravascular coagulation (DIC). The leukemic cells usually have a balanced reciprocal 
translocation between chromosomes 15 and 17 t(15;17) that results in a fusion of the promyelocytic 
leukemia  gene and the retinoic acid receptor Į gene with a differentiation-inhibitory fusion protein [9]. 
Introduction of treatment with the vitamin A-derivative all-trans retinoic acid (ATRA) has dramatically 
improved the outcome, and APL is now classified as a low-risk AML variant [9]. ATRA therapy should 
be started immediately if the diagnosis is suspected and should continue until the possibility eventually 
is excluded [11]. ATRA is currently used in combination with conventional chemotherapy, arsenic 
trioxide (ATO) may represent a therapeutic alternative [9]. 
 
Hyperleukocytosis and tumor lysis syndrome 
   Hyperleukocytosis is often defined as a peripheral blood blast count exceeding 100 x 109/l and is 
present in 10-20% of newly diagnosed AML [96]. Hyperleukocytosis with leukostatsis; e.g. pulmonary 
infiltrates and/or retinal or cerebral hemorrhages, is a medical emergency. Tumor lysis syndrome is 
then a special problem at initiation of the chemotherapy; an alternative may be hydroxyurea at 
relatively high doses (50-60 mg/kg per day) as an initial cytoreductive therapy. The effect of 
leukapheresis is controversial because few clinical studies are available [96-98].  
 
Myeloid sarcoma 
   Patients presenting with an isolated myeloid sarcoma, i.e. an extramedullary leukemic cell tumor, 
should be considered as having AML. The leukemic cells should be evaluated for genetic and 
immunophenotypic features to allow classification according to the WHO criteria. Myeloid sarcoma has 
been associated with the favorable cytogenetic abnormality t(8;21) [7], but whether the extramedullary 
disease by itself has a prognostic impact is still controversial. Patients should receive standard AML 
therapy possibly with additional local radiation therapy. 
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THE BIOLOGY OF HUMAN AML CELLS: NEW THERAPEUTIC APPROACHES TARGETING 
INTRACELLULAR PATHWAYS 
   Proliferation, differentiation, invasiveness and apoptosis of leukemic cells are partially regulated by 
external signals received from cytokines and by interactions with the local microenvironment. The 
response to these signals is, in turn, transmitted from the cell surface to the nucleus through the 
extensive series of signal transduction pathways. There is extensive cross-talk and cross-activation 
between these pathways, so that the activation of one pathway often leads to the activation of others 
[99]. The disruption of normal signaling through these pathways occurs as a result of either mutations 
of pathway components or alterations in the external signals received, e.g. from chemokines, 
cytokines or stroma [100, 101]. Conversely, many of these transduction pathways have emerged as 
potential target for pharmacological intervention in AML.  
 
The PI3K pathway 
   PI3Ks are a family of related intracellular signal transducer enzymes involved in diverse cellular 
functions such as proliferation, differentiation, migration, survival and intracellular trafficking. The 
PI3Ks phosphorylate 3-hydroxyl groups of the inositol ring of three species of phosphatidylinositol 
(PtdIns) (Figure 1).  
   The PI3K family consists of three different classes based on structural features and lipid substrate 
preferences; class I, II and III, class I is further subdivided into class IA and IB (Table 7). The activation 
of the different classes of PI3K can be caused through various pathways, but the main activators are 
RTKs, G-protein coupled receptors (GPCRs), RAS (class IA), various cytokine receptors and integrins 
(class II). In contrast to the other PI3K the class III enzymes can be directly regulated by nutrients 
such as amino acids [102]; these enzymes are thereby linked to initiation of autophagy [103] and class 
III PI3K inhibitors have been considered as inhibitors of autophagy [104]. Class I PI3K frequently have 
activating mutations in solid tumors, but this is seldom in leukemia [105]. The main product of catalytic 
class I PI3K activity is PtdIns(3,4,5)P3 (Table 7) that is rapidly converted to  PtdIns(3,4)P2 and 
PtdIns(4,5)P2 by specific phosphatases [102]. These metabolites coordinate the function and 
localization of several protein kinases, including the central regulator AKT [102]. 
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Figure 1 
The PI3K-Akt-mTOR signaling pathway.  
Upstream activation of PI3K involve different mediators, however the common feature seems to be 
activation of a receptor thyrosin kinase (RTK). PI3Ks consist of three different classes based on their 
structural features and lipid substrate preferences (classes I-III), and these enzymes phosphorylate 
the 3-hydroxyl groups of the inositol ring of three species of phosphatidylinositol (PtdIns). The Class I 
enzymes are most extensively studied and their main product PtdIns(3,4,5)P3 is rapidly converted to 
PtdIns(3,4)P2 and PtdIns(4,5)P2. These two last mediators stimulate phosphointerdependent kinase 1 
(PDK1), and thereby regulate the function and localization of several protein kinases, including AKT 
(also referred to as Protein kinase B, PKB). AKT is a serine/threonine protein kinase important for 
regulation of cellular growth and survival. At the plasma membrane AKT is phosphorylated (i) at the 
catalytic domain (Thr308) by PDK1 and (ii) within the carboxyl terminal hydrophobic domain (Ser473) 
by the mammalian target of ramapamyin (mTOR) complex 2. Both these phosphorylations are 
required for maximal AKT activation.  
   More than 100 AKT substrates have been identified, and these substrates are important for the 
regulation of apoptosis and cell cycle progression. Among the most important substrates is mTOR, a 
serine/threonine kinase with a C-terminal homology to PI3K. mTOR exist as two complexes, referred 
to as mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The interactions between PI3K-
AKT and mTORC1 are more complex. mTORC1 facilitate an inhibitory effect on PI3K, and inhibition of 
this negative feedback loop can activate AKT. 
 Abbreviations: 4E-BP1, Eukaryotic initiation factor 4E-binding protein 1; BAD, Bcl-2 antagonist of cell 
death; CHK1, Checkpoint kinase 1; FOXO, The Forkhead transcription factors; IKK, Inhibitor of țB 
kinase; JNK, c-Jun N-terminal kinase; MDM2, Murine double minute 2; mTOR, mammalian target of 
rapamycin; NF-țB, Nuclear factor ț B; P70S6K, N ribosomal protein S6 kinase; PDK1, 
phosphoinositidedependent kinase 1; PI3K, Phosphatidylinositol 3-kinase; PtdIns, 
Phosphatidylinositol; RTK, Receptor thyrosin kinase; TCS, Tuberous Sclerosis Complex. 
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Table 7. Classification of PI3K isoforms in four families according to activation pathways, 
structure, lipid substrate preferences, catalytic product and main downstream targets. (PtdIns; 
Phosphatidylinositol, RTK; receptor tyrosine kinase, GPCR; G-protein coupled receptor).  
 
Classes 
of PI3Ks 
Main 
activator 
Specific 
catalytic 
subunit 
Regulatory 
subunit Substrate Product 
Main 
downstream
activation 
 
Class IA 
 
RTKs 
GPCRs 
RAS 
 
p110Į, 
110ȕ, 
110į 
 
p50Į, p55Į, 
p55Ȗ, p85Į, 
p85Į 
 
 
PtdIns(4,5)P2 
 
PtdIns(3,4,5)P3 
 
 
 
Activation of 
AKT 
Class IB GPCRs 
 
p110Ȗ p101 PtdIns(4,5)P2 PtdIns(3,4,5)P3 
 
Activation of 
AKT 
 
Class II RTKs  
Cytokine 
receptors 
Integrins 
 
PI3KC2Į, 
PI3KC2ȕ, 
PI3KC2Ȗ 
 PtdIns 
PtdIns4P 
PtdIns3P 
PtdIns(3,4)P2 
 
Mainly 
unknown 
Class III GPCRs 
Nutrition 
(amino 
acids, 
glucose) 
 
VPS34  PtdIns 
 
PtdIns3P mTORC1 
Autophagy 
 
 
 
PI3K in AML 
   Deregulation of intracellular signaling together with transcriptional abnormalities contributes to 
leukemogenesis. The PI3K pathway is one such pathway that is frequently activated in human AML 
[106, 107]. The mechanisms leading to this PI3K/AKT activation are not completely understood. 
Mutation in the PI3K encoding gene itself is probably rare in AML [105], but other mechanisms causing 
activation may involve (i) activating mutation in the FLT3 [108] or KIT receptor [109] and RAS 
mutations [110]; (ii) autocrine/paracrine release of insulin-like growth factor (IGF-1) [111], vascular 
endothelial growth factor (VEGF) [112], hepatocyte growth factor (HGF) [113], angiopoietins (Angs) 
[114] or CXCL12 [115]; or (iii) activation of integrin-linked kinase 1 by neighboring stromal cells [116]. 
   Results from studies on the prognostic impact of PI3K activation in AML are conflicting. A favorable 
outcome in overall AML-free survival in patients with constitutive PI3K activation has been reported 
[106], while two other studies found an adverse prognostic impact [99, 117]. 
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Table 8. The main downstream targets of AKT and their most important functional effects; 
relevance to leukemogenesis in human AML 
Important AKT 
substrates AKT effect Main function 
Refs. 
 
Bcl-2 antagonist of 
cell death (BAD) 
 
Inhibition 
 
Phosphorylation by AKT in AML cells inhibits its  normal 
proapoptotic function 
 
[118] 
p21 Inhibition Binds to and inhibits the activity of different cyclin 
complexes and thereby regulates cell cycle progression 
 
[119] 
Murine double 
minute 2 (MDM2) 
Stimulation Makes a complex with p53, a potential therapeutic target 
in AML 
 
[120] 
Inhibitor of țB  
kinase (IKK)  
Stimulation Curtail for activation of NF-ƸB through both the 
canonical and non-canonical  and pathway 
 
[121] 
c-Jun N-terminal 
kinase (JNK) 
Inhibition A regulator of apoptosis, differentiation, proliferation and 
cytokine production and chemoresistance in AML 
 
[122] 
The Forkhead 
transcription 
factors (FOXO) 
Inhibition Apoptosis triggers translocation out of the nucleus on 
phosphorylation by AKT, phosphorylated FOXO3a is an 
independent adverse prognostic factor in AML 
 
[123] 
Checkpoint kinase 
1 (CHK1) 
Inhibition CHK1 phosphorylation correlates with cell cycle arrest in 
AML  
 
[124] 
Tuberous Sclerosis 
Complex (TSC) 1/2 
 
Inhibition The main inhibitory complex for mTORC1 activation [125] 
 
AKT/protein kinase B  
   AKT or protein kinase B (PKB) is a 57 kDa serine/threonine protein kinase that is a critical regulator 
of many cellular functions including proliferation, viability and metabolism. The AKT kinase family is 
comprised of three highly homologous isoforms: AKT1 (PKBĮ), AKT2 (PKBȕ) and AKT3 (PKBȖ) [126]. 
The functions of the different isoforms are not completely overlapping and isoform-specific signaling 
probably contributes to the diversity of AKT activities [126].  AKT is a downstream target of PI3K and it 
is recruited to sites in the plasma membrane that contain increased PtdIns(3,4,5)P3 and PtdIns(3,4)P2 
produced by PI3K (Figure 1). AKT is then phosphorylated at two distinct sites; (i) at the catalytic 
domain (Thr308) by phosphoinositide-dependent kinase 1(PDK1), and (ii) within the carboxyl terminal 
hydrophobic domain (Ser473) by the mammalian target of ramapamyin complex 2 (mTORC2). Both 
phosphorylation steps are needed for full AKT activation. AKT is one of the most frequently 
hyperactivated kinases in human cancers with more than 100 identified substrates (see Table 8) [127]. 
31
   Oncogenic, activating mutations in AKT have been described in solid tumors, especially breast 
cancer [128], but they are probably very rare in human AML even though they can induce leukemia in 
an animal model [128]. The most important activation of AKT in AML is mediated downstream from 
PI3K. Activation of AKT, measured by phosphorylation of Ser473, seems to occur in 50-80 % of AML 
cases [107, 117, 129] and is associated with an adverse outcome [117, 130]. Due to this prognostic 
impact AKT is regarded as a possible therapeutic target in human AML. 
 
The role of mTOR in intracellular signaling 
   mTOR is a serine/threonine kinase that has a C-terminal homology to PI3K and therefore belongs to 
the PI3K-related kinase family [131]. It has a key role in several signaling pathways both in normal and 
malignant hematopoiesis. mTOR functions as a sensor to ensure that the cell is in an appropriate 
nutritional and bioenergetic state, and it thereby supports cell growth by modulating a wide range of 
processes, including protein synthesis, ribosome activity and autophagy [131]. 
   mTOR exists as two complexes referred to as mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTORC2 can phosphorylate the Ser473 residue on AKT and is thereby necessary for the 
maximal activity of AKT. The upstream activation of mTORC2 is mainly unknown, whereas the 
interactions between PI3K-AKT and mTORC1 are better characterized. Firstly, mTORC1 can be 
activated by PI3K through the downstream signaling via AKT and the TSC1-TSC2 complex [125] 
(Figure 1).  Secondly, mTORC1 has an inhibitory effect on PI3K and inhibition of this negative 
feedback loop can thereby activate AKT [132]. Thirdly, mTORC1 can also be activated through 
signaling in other intracellular pathways [133]. Thus, the interactions between the two mTOR 
complexes and the AKT pathway are very complex and the final functional effects are difficult to 
predict. 
   The two best characterized downstream targets of mTORC1 are the ribosomal protein S6 kinase 
(P70S6K) and the eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) [132]. P70S6K is 
phosphorylated and activated by mTORC1 and is involved in ribosomal protein synthesis. In contrast, 
4E-BP1 is inhibited by mTORC1. The function of 4E-BP1 is complex, one major effect being a 
negative regulator of the initiation of protein synthesis. Consequently, the main role of mTORC1 is 
stimulation of protein synthesis, and mTORC1 has therefore been linked also to autophagy [132]. 
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   The concomitant activation of PI3K/AKT and mTOR is frequently observed in several cancers [127], 
and mTOR activation seems to depend particularly on the PI3K/AKT pathway. PI3K/AKT is activated 
in 50-80% of AML cases [107, 117, 129], but mTOR is activated in almost all AML cases [134]. This 
indicates that additional activating pathways proably are involved, supported by the observation that 
PI3K inhibition does not entirely suppress mTOR activity [134]. One possible pathway is then the Src 
kinase Lyn that is frequently phosphorylated and activated in AML [135]. 
 
Pharmacological targeting of PI3K-AKT-mTOR 
   Several inhibitors of the PI3K-AKT-mTOR have been developed [136, 137]. Some of these inhibitors 
are specific for mTOR, PI3K or AKT, respectively. Other inhibitors are dual inhibitors of mTOR and 
PI3K (Table 9). The mTOR inhibitors everolimus (RAD001) and deforolimus (AP23573) have been 
evaluated as monotherapy in patient with relapsed or refractory hematological malignancies [138, 
139], whereas sirolimus has been evaluated in combination with MEC (mitoxantrone, etoposide and 
cytarabine) in patients with relapsed and refractory AML [140]. The mTOR inhibitors were then 
generally well tolerated [137, 139], but the effect in combination-therapy [140] as weel as in mono-
therapy seems to be limited [138, 139]. However, the effect may be more important in certain subsets 
of patients [138, 140]. Future studies are therefore warranted both to define patients eligible for this 
treatment and to determine the optimal dose and drug combination. This should also include the 
further evaluation of mTORC2 inhibitors [132]. 
   A possible therapeutic strategy is to use mTOR inhibitors after allo-SCT. Rapamycin as well as other 
mTOR inhibitors have been used for graft versus host disease (GVHD) prophylaxis, and these drugs 
may then have an additional direct antileukemic effect. Preliminary clinical results are promising with 
low non-relapse mortality when combining tacrolimus and sirolimus for GVHD prophylaxis [141]. 
Microangiopathy is a possible side effect, and for this reason mTOR inhibitors should possibly be used 
with caution in patients receiving conditioning regimens that cause increased endothelial damage, 
e.g.busulfan/cyclophosphamide [141]. Finally, so far only specific mTOR inhibitors have been 
evaluated in clinical trials for AML, but other inhibitors of the PI3K/AKT/mTOR pathway are also 
considered, including specific PI3K inhibitors, AKT inhibitors and dual PI3K/mTOR inhibitors [142, 
143].  
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Table 9. 
Inhibitors of the PI3K-AKT-mTOR pathway currently included in clinical trials. 
*) Evaluated or currently under evaluating in AML patients. 
PI3K inhibitors mTOR inhibitors 
BGT226 [144] Rapamycin/Sirolimus* [138, 141] 
XL147 [145] Everolimus/RAD001* [139] 
BKM-120* [146] Temsirolimus/CCI-779 [147] 
GDC-0941 [148] Deforolimus(AP23573)*  [140] 
SF1126 [149] Ridaforolimus (MK8669) [150] 
LY294002 [151]   
PX-866 [152]   
    
Dual mTOR/PI3K inhibitors AKT inhibitors 
 
PI-103 
 
[153, 154] 
 
GSK2141795 
 
[155] 
NVP-BEZ235 [142, 156]  SR13668 [157] 
PF-04691502 [158] GSK690693 [159] 
XL765(SAR245409) [160] MK-2206* [161] 
AZD8055 [162] Perifosine [143] 
    
 
 
THE BIOLOGY OF HUMAN AML CELLS:  FUNCTION AND THERAPEUTIC TARGETING OF THE 
HEAT SHOCK PROTEIN SYSTEM  
 
   Heat shock proteins (HSPs), also called stress proteins, represent a group of ubiquitous proteins 
that are expressed at low levels under normal physiological conditions, but increased production is 
triggered by exposure to environmental stress [163]. This is often referred to as the heat shock 
response [163]. This response can be triggered by malignant transformation, infections, inflammation, 
exposure to toxins, starvation, oxygen deprivation, nitrogen deficiency or water deprivation [164].    
   HSPs are usually cytoplasmic proteins, but there is also an increasing interest for a potential 
extracellular role of HSPs [165, 166]. They act as molecular chaperons together with a group of 
cochaperones, and play important roles in protein-protein interactions and assisting in proper protein 
conformation with prevention of unwanted protein aggregation. The HSPs are named according to 
their molecular weights, e.g. HSP60, HSP70 and HSP90 (Table 10). In contrast to HSP70 that controls 
folding of all newly synthesized proteins, HSP90 has a more restricted repertoire of client proteins 
mainly including various protein kinases [167, 168]. HSP90 seems to be important for cellular 
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proliferation, survival and adaptation to unfavorable microenvironments, and HSP90 inactivation 
results in inappropriate function and rapid degradation of its client proteins [169]. 
 
Table 10. 
The most common HSPs and their main physiological functions 
Heat shock 
protein 
Main function 
HSP27 Protection against protein aggregation, regulation of signaling in the 
apoptotic pathway, regulation of cell movement. 
HSP60 Promotes efficient mitochondrial protein folding, the main function in cytosol 
is to induce folding of actin and tubulin.  
HSP70 Stabilizes proteins prior to complete folding, regulates transport across 
membranes and proteolysis. 
HSP90 Stabilizes kinases prior to complete folding or activation; forms stable 
complexes with several transcription factors. 
HSP110 Dissociates protein aggregates, facilitates proteolysis, essential for 
thermotolerance. 
 
 
   HSP synthesis is strictly regulated both through (i) activation and nuclear translocation of the 
transregulatory heat shock transcription factors (HSFs), and (ii) at the level of translation of mRNA into 
protein [170]. Cells constitutively express HSF proteins, but these proteins do not induce HSP 
expression genes in the absence of stress reactions. In mammalian cells, HSF1 is maintained in the 
cytoplasmatic HSP90 complex as a monomer that lacks DNA binding activity [171]. This complex 
dissociates in response to stress and releases the HSF1 monomer (Figure 2). The monomer then 
forms a trimer capable of DNA binding [171].  
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Figure 2 
Activation of HSP90 transcription.  
   HSF1 is maintained in the cytoplasmatic HSP90 complex as a monomer that lacks DNA binding 
activity. This complex dissociates in response to accumulation of denaturated proteins, and releases 
the HSF1 monomer. The monomer then forms a trimer that translocates to the nucleus and binds to 
HSE. Transcription is initiated resulting in increased HSP90 translation in cancer cells.  
Abbreviations: HSE, Heat shock element; HSF1, Heat shock transcription factor 1. 
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   Exposure to anticancer agents can induce expression of HSP90 and thereby enhance 
chemoresistance and cellular recovery after this exposure. Molecular chaperones have been 
implicated in resistance to anticancer treatments; this is summarized in Table 11. Several HSP90 
client proteins have been validated as possible therapeutic targets in cancer treatment, and HSP90 
inhibition thereby makes it possible to target several intracellular pathways, including oncoprotein-
initiated signaling [169]. Furthermore, HSP90 in malignant cells is often present entirely in 
multichaperone complexes with high ATPase activity, whereas HSP90 in normal tissues is present in a 
latent, uncomplexed state [172]. All these characteristics suggest that HSP90 should be regarded as a 
possible unique target for antileukemic therapy.  
 
HSP90 expression and interaction with important client proteins in AML 
   The expression of HSPs by leukemic cells varies between patients [173-175]. Complete remission 
rates and overall survival seem to be higher in patients with generally low HSP expression [174, 176], 
wheares HSP90 expression has no correlations with white cell counts, morphology (i.e. FAB 
subclassification) or cytogenetics [176]. Similar observations have been made for patients with 
preleukemic MDS where high HSP90 expression is seen especially in the high-risk subgroups [177]. 
FLT3 is a HSP90 client protein and inhibition of HSP90 thereby seems to have an indirect inhibitory 
effect on FLT3-dependent intracellular signaling [178]. Mutated FLT3 is constitutively activated and 
probably mediates signaling that is important both for leukemogenesis and chemosensitivity, and the 
combination of conventional DNA-damaging therapy with agents that mediate direct (TKIs) or indirect 
(HSP90 inhibitors) FLT3 inhibition should therefore be considered in AML therapy [179]. Other HSP 
client proteins are probably also involved in leukemogenesis [169], some of the most important being 
summarized in Table 11. The importance of HSP90 and some of its client proteins for intracellular 
signaling and intercellular crosstalk will be discussed below. The transcription factor NF-țB controls a 
wide range of genes regulating proliferation and apoptosis, and this is probably true also for primary 
human AML cells [121]. HSPs can interact with the function of NF-țB [121] through (i) binding and 
possibly neutralization of pro-apoptotic or pro-inflammatory NF-țB targets; and (ii) stabilization/binding 
of both the main NF-țB regulators IțB kinase (IKK) [180] and NF-țB inducing kinase (NIK) [181]. 
These observations suggest that pharmacological targeting of chaperones in AML should be further 
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explored [182], and this is further supported by experimental studies suggesting that the role of FLT3 
in leukemogenesis involves NF-țB [183].  
   The two structurally unrelated protein kinases CHK1 and CHK2 are emerging as key mediators in 
cellular responses to genotoxic stress [184]. Recent studies suggest an important role of both these 
kinases in the network of genome surveillance pathways that coordinate cell cycle progression with 
DNA repair and apoptosis regulation. These kinases thus provide a linkage between upstream 
sensors of cell cycle checkpoints and cell cycle regulation [185]. DNA damage and replication stress 
will activate the CHK1 signaling pathway, block S phase progression and thereby participate in G2 
arrest. Furthermore, AML cells exposed to cytotoxic agents often show cell cycle arrest at the G2/M 
checkpoint together with development of chemoresistance [186].  CHK1 inhibition may then allow 
checkpoint exit with induction of chemosensitivity [187]. HSP90 is important for the folding and 
stabilization of CHK1 [188] and as expected HSP90 inhibition depletes CHK1, disrupts the S-phase 
checkpoint and enhances the therapeutic effect of cytarabine in primary AML cells [124].  
   Finally, the matrix metalloproteases (MMPs) are important in the regulation of apoptosis, proliferation 
and angiogenesis [101]. MMP-2 and MMP-9 are the quantitative most important ones [101], and these 
proteases can be released from primary AML cells [189]. Both MMP-2 and MMP-9 interact with 
HSP90 [165, 190], showing that this HSP is also important for the extracellular compartment [191]. 
HSP inhibition significantly reduces the level of these proteases in in vitro models of AML [175].   
 
HSP90 inhibition 
   HSP90 possesses two binding sites for client proteins located in the N- and C-terminal fragments, 
respectively. The C-terminal fragment binds partially folded proteins in an ATP-independent way and 
is potentially regulated by cochaperones. The N-terminal domain contains a peptide binding site that 
binds preferentially peptides longer than ten amino acids, and peptide dissociation is induced by ATP 
binding [192, 193]. The majority of HSP90 inhibitors blocks the N-terminal ATPase activity [169]. The 
benzoquinone amsancines such as geldanamycin were the first HSP90 inhibitors to be developed 
[194]. Geldanamycin had several pharmacological limitations, including poor solubility, limited in vivo 
stability and hepatic toxicity and is not ivestigated further in clinical studies [195]. However, more 
soluble derivates such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), 17-
dimethylalaminoethylamino-17-demethoxygeldanamycin (17-DMAG, alvespimycin) and retaspimycin  
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Table 11. Main client protein of HSP90 in AML. 
Client proteins Relevance to human AML Key references 
 
Chaperones and relatives 
  
Heat shock protein 70 (HSP70) Cochaperone of HSP90, expression closely 
correlated to HSP90 expression 
[175] 
Nuclear distribution C (NudC) Important for nuclear migration in cell division, high 
expression in human AML cells  
[196] 
 
Transcriptional regulation 
  
p53 Important for regulation of primary AML cell viability 
in vitro and in vivo  
[197] 
Murine double minute 2 
(MDM2) 
A downstream target of AKT, the p53-MDM2 
complex is a possible therapeutic target in AML  
[120] 
Signal transducer and activator 
of transcription-3 (STAT3) 
Important intracellular mediator downstream to 
hematopoietic growth factor receptors  
[198] 
 
Kinases 
  
FMS-like tyrosine kinase 3 
(FLT3) 
Mutated FLT3 is an adverse prognostic factor in 
human AML, FLT3-ligand is a growth factor for 
primary human AML cells for most patients  
[36] 
c-Jun N-terminal kinase (JNK) A kinase involved  in apoptosis, differentiation, 
proliferation, cytokine production and 
chemoresistance in AML 
[122] 
KIT The second most frequently mutated RTK, often 
mutated in CBF-AML 
[52] 
AKT Important downstream mediators for hematopoietic 
growth factor receptors in primary human AML cells  
[117] 
Cyclin B 
 
A cell cycle regulator expressed in cytoplasm and 
nucleus of primary human AML cells, a possible 
leukemia-associated antigen  
[199] 
Checkpoint kinase (CHK1) 
 
A downstream target of AKT, there phosphorylation  
correlates with cell cycle arrest in AML  
[124] 
Bcr-Abl 
 
Involved in malignant transformation in CML, can be 
mutated in AML  
[200] 
 
Janus kinase 1 (JAK1) 
 
Can be mutated in primary human AML cells and 
has a disease-modifying effect  
[49] 
 
Insulin-like growth factor 1 
receptor (IGF-1 receptor) 
Insulin stimulate primary AML cell proliferation  
 
[201] 
Inhibitor of țB  kinase (IKK)  
 
Downstream target of AKT, activates the NF-țB 
complex trough both the canonical and non-
canonical pathway  
[121] 
NF-țB-inducing kinase (NIK) Activates the NF-țB complex through the non-
canonical pathway 
[121] 
 
Others 
  
Matrix metalloprotease 2 (MMP-
2) 
Expressed by AML cells, and has a possible 
adverse prognostic effect 
[189] 
Matrix metalloprotease 9 (MMP-
9) 
Expressed by AML cells, especially with monocytic 
differentiation 
[189] 
Survivin 
 
Inhibitor of apoptosis with a possible adverse 
prognostic impact in AML 
[202] 
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(IPI-504) and 17-allylaminogeldanamycin (17-AG) have entered clinical studies [203]. The natural 
occurring inhibitor radicicol was also early discovered as a HSP90 inhibitor in laboratory model [169]. 
This compound lacks in vivo effect, but more potent derivates have been developed and have now 
entered clinical trials (Table 12). Several synthetic drugs have been obtained by rational design from 
the crystal structures of the HSP90 binding pocket [204, 205] (Table 12), some of them have shown 
promising preclinical results have entered clinical trials (Table 12).  
   The first clinical trials with HSP90 inhibitors have been reported [206-208], including studies in AML 
[209, 210]. It should be emphasized that the large majority of the patients in these studies had 
advanced solid tumors [206-208, 211] or relapsed or refractory hematological malignancies [209, 210, 
212].  Based on these studies it can be concluded that it is possible to achieve pharmacological 
HSP90 inhibition with acceptable toxicity in a majority of patients with advanced cancers. However, 
further studies are warranted to investigate potential effects of combination therapy, the optimal time to 
start treatment and to define subgroups of patients with special benefit of HSP90 inhibition [213].   
 
 
Table 12. HSP90 inhibitors in clinical trials. Evaluated or under evaluating in AML   
 
Functional 
classification
 
Name of inhibitor 
 
Main administration 
 
Key references 
Tanespimycin, 
17-AAG, KOS-953, CNF110 
 
Intravenous 
 
[206-208, 212] 
Alvespimycin, 17-DMAG* Intravenous [209] 
Retaspimycin, IPI-504 Intravenous [211] 
 
Benzoquinone        
ansamycins/ 
Geldanamycin 
derivates 
 
IPI-493, 17-AG* Oral [214] 
 
 
AT13387 
 
Oral 
 
[215] 
 
Radicicol derivates 
NVP-AUY922* Intravenous [216] 
 
MPC-3100 Oral [217] 
BIIB021, CNF2024 Oral [218] 
Debio 0932,CUDC-305 Oral [219] 
KW-2478 Intravenous [220, 221] 
SNX-2112 Oral (by prodrug 
SNX-5422) 
[222] 
STA-9090* Intravenous [210] 
Synthetic 
XL888 Oral [223] 
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THE BIOLOGY OF HUMAN AML CELLS:  THERAPEUTIC TARGETING OF NF-țB MEDIATED 
INTRACELLULAR SIGNALING  
   The NF-țB family of transcription factors was identified 25 years ago as a nuclear factor that binds 
the ț light chain enhancer in B-cells [224]. Several studies suggest a role of NF-țB in leukemogenesis 
including both through its direct effects in AML cells and indirect effects through bi-directional crosstalk 
between leukemic cells and their neighboring stromal cells [121]. Studies have described constitutive 
activation with nuclear localization of NF-țB in primary human AML cells [225]. The NF-țB activity 
could not be detected in normal CD34+ hematopoietic cells, and as expected pharmacological NF-țB 
inhibition in vitro then induced apoptosis only in AML cells but not in normal CD34+ cells [225]. The 
NF-țB family consists of the five different transcription factors RelA, RelB, c-Rel, p50 and p52 (Table 
13) that bind to their response elements as hetero- or homodimers [121].  
 
Table 13. The most common nomenclature and the encoding genes of the five proteins in the 
mammalian NF-țB family 
 
Proteins Alternative names Genes 
 
RelA 
 
p65, NF-țB3 
 
RELA 
RelB  RELB 
c-Rel Rel REL 
p50 p105, NF-țB1 NFKB1 
p52 p100, NF-țB2 NFKB2 
 
   Under basal conditions this moiety is inactivated in the cytoplasm by the inhibitor IțB, but in 
response to specific stimulation IțB is degraded and NF-țB is thereby released and can bind other 
proteins, DNA or RNA. There are two pathways for activation of NF-țB: the canonical and the non-
canonical pathway [121]. Inhibitory IțB is then phosphorylated on highly conserved serine residues by 
an IKK complex formed by the three subunits IKKĮ, IKKȕ and IKKȖ; this leads to ubiquitination and 
proteasomal degradation of IțB. NF-țB can thereby translocate to the nucleus and induce 
transcription. On the other hand, the non-canonical pathway involves a further activation step through 
the NIK, which secondarily stimulates IKK-induced phosphorylation (Figure 3).  
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   Once translocated to the nucleus NF-țB promotes cell survival by initiating transcription of genes 
encoding stress-response enzymes, cell-adhesion molecules, pro-inflammatory cytokines and anti-
apoptotic proteins (Figure 3). The pre-existing balance between expression of genes involved in 
regulation of survival and apoptosis may ultimately determine whether the cell undergoes apoptosis in 
response to NF-țB activation or inhibition [226]. Under physiological conditions activation of NF-țB 
triggers expression of antiapoptopic genes [227, 228]. The balance is thereby altered in favor of 
apoptosis by NF-țB inhibition, and this seems to be true also in human AML where targeting of IKK 
with the specific inhibitor AS602868 blocks NF-țB activation and thereby leads to apoptosis [229]. In 
addition to the antiapoptotic effects, NF-țB also has a growth stimulating effect of malignant cells by 
inducing cell cycle progression and hence increased proliferation of the malignant clone [121]. NF-țB 
and IKK-controlled pathways are also important functional modulators not only in the malignant cell but 
also in surrounding stromal cells, and these cells also take part in the leukemic process in human AML 
(Table 15)  [230, 231]. 
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Figure 3 
Activation of the NF-NB pathway.  
   The canonical pathway (left part) activates the IțB kinase (IKK) complex leading to inactivation of 
inhibitor țB (IțB); the IțB is thereby degraded by the proteasome with loss of NF-NB inhibition and 
translocation of RelA/p50 to the nucleus. Alternatively, in the noncanonical pathway (right part) NF-țB 
inducing kinase (NIK) acts via IKK, to phosphorylate p52 that forms a complex with NIK and RelB. In 
both pathways the released NF-țB dimmer, p50/Rela and p52/Rel B respectively, is thus able to 
translocate to the nucleus where it binds to specific DNA promoters, initiating transcription of genes 
that encode stress-response enzymes, cell-adhesion molecules, pro-inflammatory cytokines and anti-
apoptotic proteins 
Abbreviations: IțB, inhibitor țB; NIK, NF-țB inducing kinase; IKK, IțB kinase. 
   Cells that display chemokine receptors can respond to chemokine gradients with chemotactic 
migration due to activation of multiple intracellular signals including NF-țB [232], and malignant 
transformation associated with constitutive NF-țB activation leads to endogenous expression of 
chemokines and their receptors [233]. The cytokine release in the bone marrow microenvironment 
may create autocrine and paracrine loops that keep NF-țB in an activated state. This has been 
described for human fibroblasts where CXCL8 increased the expression of its receptor CXCR2 that in 
turn led to higher CXCL8 (IL-8) release in vitro through NF-țB signaling [234]. CXCL8 can thereby 
promote neoplastic growth through its effect on various cells in the cancer cell microenvironment [235]. 
   NF-țB plays a crucial role in angiogenesis. Several of the angiogenic factors (e.g. VEGF and 
CXCL8) are regulated by NF-țB, and their constitutive release by malignant cells is suppressed by 
NF-țB-inhibition [121]. Upregulation of Ang-1 expression in both fibroblasts and endothelial cells 
occurs via the NF-țB signal transduction pathway [236, 237]. NF-țB also promotes expression of 
several MMPs, including MMP-2 and MMP-9 [238].  
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NF-țB inhibition   
   Numerous natural products and synthetic compounds can inhibit NF-țB, and recently more specific 
NF-țB inhibitors have been developed [121, 239] (Table 14). The experience from preclinical studies 
of the specific IKK inhibitors suggests that NF-țB inhibition can eradicate primary human AML cells at 
the bulk, progenitor and stem cell level [240].  
 
Table 14. Important NF-țB inhibitors 
Classification Important compounds 
 
 
Modulators of IKK activity  
 
AS602868 
MLB120 
BMS-345541, BAY11-7085 
Thalidomide,lenalidomide 
DNMT inhibitors, HDAC inhibitors 
 
 
Proteasome inhibitors 
Bortezomib 
MG262 
CEP-18770 
 
   Among the most promising drug that also functions as a NF-țB inhibitor in the treatment of 
hematological malignancies is the proteasome inhibitor bortezomib [241, 242]. The mechanisms of 
action for proteasome inhibitors are complex and include additional mechanisms and not only NF-țB 
inhibition [228]. The final step before NF-țB translocation is ubiquitin-dependent degradation of IțB by 
the 26S proteasome [239], and inhibitors of the ubiquitin-proteasome pathway suppress activation of 
NF-țB by stabilizing IțB. Thalidomide and its derivate lenalidomide, that lacks the neurotoxic side 
effects associated with the parent drug, have complex pharmacological effects that can be divided into 
three major groups; (i) a direct anti-neoplastic effect, (ii) indirect effects mediated via neighboring cells 
in the neoplastic microenvironment, and (iii) immunomodulation [243]. The drugs attenuate the 
phosphorylation of IKK as well as the RelA subunit; and all three pharmacological effects are at least 
partly mediated by NF-țB inhibition. Both drugs are widely used in the treatment of multiple myeloma 
(MM) [244], and their use in AML therapy is considered, especially of AML secondary to MDS [245]. 
These studies have provided evidence for antileukemic activity, especially indirect antiangiogenic 
activity, but the clinical effect of single agent thalidomide in AML seems limited [246]. Lenalidomide 
seems particularly effective in patient with 5q deletion [247] and trisomy 13 [248].  
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   More specific inhibition of IKK is a very attractive therapeutic strategy. Several IKK inhibitors have 
been identified; they have not been investigated in clinical studies, but the preclinical results of some 
agents seem promising. These preclinical studies suggest that the sensitivity to IKK inhibitors 
correlates with the basal NF-țB activity and the drugs modulate adhesion molecule expression [121], 
and several agents have also been shown to target even leukemic stem cells (LSCs) [121].  
 
THE BONE MARROW MICROENVIRONMENT: NORMAL AND LEUKEMIC BONE MARROW 
 
The bone marrow organization at the macro- and microscopic level 
   The bone marrow constitutes 4% of the total body weight in humans. The red marrow consists 
mainly of hematopoietic tissue and the yellow marrow mainly of fat cells. At birth all the bone marrow 
is red, whereas with increasing age this is reduced and in adults approximately half of the marrow is 
red, i.e. mainly the marrow in the pelvic bones, skull, sternum, vertebrae, costa and the proximal 
extremity bones (femur and humerus). The non-hematopoietic cells of the marrow are referred to as 
the stroma (Table 15), and these cells provide a microenvironment that facilitates hematopoiesis. 
 
Table 15. Bone marrow stromal cells 
Cell type Main Function 
 
Fibroblasts 
 
Synthesis of collagen, glycosaminoglycans and glycoproteins; the main 
component of the extracellular matrix 
 
Osteoblasts 
 
Responsible for bone formation and mineralization, supporting the 
hematopoietic cells, forming endosteal stem cell niches 
 
Osteoclasts 
 
Involved in bone resorption by removing mineralized bone  
Endothelial cells 
 
 
Surrounding the vascular system, acting as a barrier between the vessel 
lumen and surrounding tissue, supporting hematopoiesis and forming the 
vascular stem cell niches 
 
Adipocytes 
 
Cells specialized in storing energy 
 
 
   The main function for the red bone marrow is to produce mature blood cells. These cells originate 
from the hematopoietic stem cell (HSC). The definition of a stem cell is under debate, but there is a 
general agreement that these cells (i) show self-renewal, i.e. have the ability to go through numerous 
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cell divisions while maintaining the undifferentiated state; and (ii) have the potential to differentiate into 
specialized cells (potency). This potency can be classified as described in Table 16. 
 
Table 16. Stem cell potency. 
Potency Definition Example 
 
Totipotency  
 
Cells with the ability to divide and produce all the differentiated 
cells in an organism, including extraembryonic tissues 
 
 
Zygote 
Pluripotency  Cells that have the potential to differentiate into any of the three 
germ layers: endoderm, mesoderm or ectoderm 
 
Embryonic stem 
cell 
Multipotency Cells that have the potential to give rise to cells from several, 
however limited number of lineages 
 
Hematopoietic 
stem cell 
Oligopotency  Cells with the ability to differentiate into a few cell types Common myeloid 
progenitor cell 
 
Unipotency Cells that have the capacity to develop/differentiate into only one 
distinct cell type 
Erythroblast 
 
   The HSCs are multipotent stem cells with the capacity of self-renewal, giving rice to oligopotent 
myeloid or lymphoid progenitors. The bone marrow stroma represents a supportive network of the 
HSCs [249] that are thought to reside within specific niches (Figure 4). These niches are specialized 
microenvironments created by supportive cells that facilitate stem cell survival and self renewal 
through expression of membrane molecules and release of soluble mediators. HSCs tend to reside 
near the endosteal surface [250], and studies of HSCs homing after transplantation in animal models 
have documented redistribution of HSCs to the endosteal region [251]. This is currently referred to as 
the osteoblastic or endosteal niche located at some distance from the blood supply in a relatively 
hypoxic microenvironment [252]. The hypoxia is probably important for maintenance of pluripotency 
and self-renewal capacity [252]. The major molecular response to the hypoxia is increase in the 
transcription factor hypoxia-inducible factor-1 (HIF-1). HIF-1 binds to responsive target regulatory 
sequences of multiple genes involved in energy metabolism, myelopoiesies and angiogenesis [252], 
several of these probably being important for HSC maintenance. One well-characterized HIF-1 target 
involved in HSC maintenance is VEGF, which is important for survival and repopulation of HSCs [253]. 
However, several other molecules are also involved in direct crosstalk or paracrine interactions 
supporting maintenance, including the Notch [254], and Ang-Tie2 systems [255] . Pharmacological 
targeting of both these systems is currently considered in hematological malignancies [230, 254].  
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   Although the endosteal niche is believed to be the main facilitator of HSCs maintenance and 
quiescence, a large part of the HSCs are found adjacent to sinusoids in the so called vascular niches 
(Figure 4) [249]. This is possibly an explanation why HSCs can rapidly be recruited to the peripheral 
circulation during clinical stem cell mobilization. Whether endothelial cells contribute to maintenance of 
HSCs or whether HSCs only transiently migrate trough the vascular niche is not known [249]. 
 
Figure 4 
Hematopoietic stem cells niches. 
   Trabercular long bone is richly vascularised, giving rise to organization of distinct stem cell niches; 
e.g. the endosteal niche and the vascular niche. Hematopoietic stem cells, and probably also leukemic 
stem cells, can reside to both these niches, although hematopoietic stem cells tend to localize near the 
endostial surface. Osteoblasts and other supporting cells are involved in direct crosstalk or paracrine 
interactions that support the maintenance of the hematopoietic stem cells. Hematopoietic stem cells 
are also found adjacent to sinusoids in the vascular niche, explaining why hematopoietic stem cells 
can rapidly be recruited to the peripheral circulation. Whether endothelial cells contribute to 
maintenance of hematopoietic stem cells or whether they only transiently migrate trough the vascular 
niche, is mainly unknown. 
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Leukemic stem cells 
   The theory that most cancers contain a minor population of functionally distinct cancer stem cell has 
been postulated for several years. The theory is controversial [256], but in the case of AML there is 
growing support for existence of such LSC [257]. These fractions of cells probably count for one per 
million of the whole leukemic blast population [257]. The cells are usually located within the 
CD34+/CD38- compartment [257] and are able to recapitulate the disease in mouse xenograft models 
[257]. However, LSC can probably also rest in other compartments, especially the CD34+/CD38+ 
compartment [258]. Thus, LSCs show both self-renewal and a capacity to produce leukemic 
progenitors with proliferative but not self-renewal capacity [256], and similar to their normal 
counterparts they are dependent of support from the bone marrow microenvironment [259]. LSCs also 
engraft and reside in the endosteal niche in murine models [260], most of them are in the Go phase 
and are relatively resistant to cytarabine treatment [259, 260]. Selectively inhibition of LSCs has now 
emerged as a possible therapeutic strategy [256]. 
 
THE BONE MARROW MICROENVIRONMENT: ANGIOGENESIS AND THE ANGIOREGULATORY 
NETWORK IN AML 
 
   Angiogenesis is regulated by angiogenic activators and inhibitors, and the shift in the normal 
homeostatic balance in favor of angiogenesis is often referred to as the angiogenic switch [261]. 
Cancer-associate angiogenesis was originally described in solid tumors [262], but more recent studies 
have brought attention to angiogenesis as important for development, progression and prognosis in 
hematological malignancies: 
x Bone marrow microvessel density (MVD) is often increased in hematological malignancies, 
especially in patients with advanced stage disease [263]. 
x Antiangiogenic therapy causes vascular disruption and has antileukemic effect [264]. 
x The crosstalk between leukemic and microvascular endothelial cells can increase the 
proliferation of both the endothelial [265] and leukemic cells [266]. 
x The use of magnetic resonance techniques can provide functional imaging of bone marrow 
vascularity that can possibly be used for prognostication in AML [267]. 
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Several mediators have been postulated to have pro- or antiangiogenic effects, and some of the most 
important angioregulators in human AML will be described below. 
 
VEGF 
   There are five members of the mammalian VEGF family: VEGFA, VEGFB, VEGFC, VEGFD and 
placental growth factor. VEGFA (hereafter referred to as VEGF) is a growth and survival factor for 
vascular endothelial cells, and it is well characterized for its role in developmental and pathological 
angiogenesis [268]. VEGF is highly expressed in several human cancers, this is at least partly caused 
by its transcriptional upregulation by hypoxia and by various oncogenes [268]. VEGF can be released 
both by malignant cells, including AML blasts, and by surrounding stromal cells [269]. It binds and 
activates the two related RTKs of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2). Most 
of the activities attributed to VEGF are mediated by signaling through VEGFR2, including its mitogenic 
as well as survival and motility enhancing effects. The role of VEGFR1 in angiogenesis is controversial 
and less well understood. VEGFR2 is predominantly found in endothelial cells where its activation is 
critical for blood vessel formation, migration, differentiation and vascular permeability. Several 
strategies have been tried to inhibit these effects [268], including (i) neutralizing antibodies to VEGF or 
VEGFRs; (ii) soluble VEGFRs or chimeric receptors that trap circulating VEGF and (iii) -VEGFR TKIs. 
VEGF-targeted agents in clinical use in Norway include the VEGF-specific monoclonal antibody 
bevacizumab, and the TKIs sorafenib, sunitinib and pazopanib.  
 
HGF 
   HGF binds to its receptor mesenchymal-epithelial transition factor (MET); MET is expressed by cells 
of epithelial origin whereas HGF is produced by mesenchymal cells, and HGF is the only known MET 
ligand [113]. HGF can be produced both by bone marrow stromal cells [270] and by AML blasts [231], 
and high serum levels are associated with an adverse prognosis in AML [271, 272]. HGF binding to its 
receptor activates the RTK activity, initiates intracellular protein phosphorylation and thereby several 
intracellular signaling cascades; the two most important being the PI3K and STAT pathways [113]. 
MET activation then leads to a proliferative, invasive, antiapoptotic and angiogenic phenotype of 
endothelial cells. HGF/MET has emerged as potential therapeutic target in cancer therapy, and these 
inhibitors can be divided in two main subclasses; (i) biological HGF/MET antagonists and (ii) synthetic 
MET kinase inhibitors [273]. The biological antagonists include truncated or uncleavable HGF forms 
49
that antagonize full-length HGF binding and neutralizing monoclonal antibodies directed against HGF 
or MET [113, 273]. The MET kinase inhibitors competitively antagonize the intracellular ATP binding 
site, thereby preventing the RTK-mediated intracellular phosphorylation cascade [113, 273]. 
Compounds in both classes have now entered early clinical trials [273]. 
 
Chemokines 
   Chemokines are small chemotactic cytokines with a molecular weight of 8-10 kDa. They are divided 
into four subgroups (C, CC, CXC, CX3C) based on the presence of amino (N)-terminal cysteine 
residues; the largest are the CC and the CXC chemokines [100]. The chemokines have a complex 
angioregulatory role [274], and they can be classified as proangiogenic or angiostatic, e.g. facilitators 
or inhibitors of angiogenesis, respectively. The most important angiogenic and angiostatic chemokines 
are briefly described in Table 17 [100, 274, 275]. 
 
Table 17. Angiogenic and angiostatic chemokines; the most important chemokines 
(corresponding receptors) are given in the upper part and their main functions in the lower. 
Angiogenic chemokines Angiostatic chemokines 
 
CCL1 (CCR8) 
CXCL4 (CXCR3B) 
CCL2 (CCR2) CXCL9 (CXCR3B) 
CCL3 (CCR5) CXCL10 (CXCR3B) 
CXCL1 (CXCR2) CXCL11 (CXCR3B) 
CXCL8 (CXCR2) 
 
 
Main angiogenic function Main angiostatic function 
 
Recruitment of angiogenic hematopoietic cells 
 
Recruitment of T-cells which induce expression 
of angiostatic factors 
Activation of endothelial cell chemotaxis and 
tubular formation 
Activation of endothelial cell apoptosis and 
regression 
Stimulating angiogenic growth factor signaling Inhibition of angiogenic growth factors 
Direct stimulating and activation of RTKs 
 
Direct binding and inhibition of RTKs 
 
   Primary human AML cells generally show constitutive release of several angioregulatory 
chemokines [233], the highest levels are usually seen for proangiogenic CXCL8 [233]. Antiangiogenic 
chemokines, e.g. CXCL9-11, can also be released but usually at lower levels than CXCL8 [233].    The 
only chemokine yet to be a pharmacological target is CXCR4, and the specific inhibitor plerixafor is 
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now used for stem cell mobilization [276]. However, this drug is also investigated as a possible 
antileukemic agent and is tried in the treatment of AML [276].  
 
Ang and Tie system 
   Tie1 and Tie2 constitute a distinct family of RTKs expressed mainly by endothelial cells. Their 
naturally occurring agonists are the Angs that constitute four different classes (Ang1-4). Ang1 and 
Ang2 are the most important agonists, and Tie2 is the most relevant receptor in angiogenesis. Ang1 is 
a Tie2 agonist, whereas the role of Ang2 is more complex. Ang2 can be a competitive Tie2 antagonist 
for Ang1 in endothelial cells [277], but more recent studies have demonstrated that Ang2 is a context-
dependent partial agonist/antagonist of Tie2 signaling [278]. The function of Ang2 then seems to 
depend on cell and tissue localization, developmental stage of the cells, Ang2 concentration and 
duration of exposure [279]. Furthermore, Ang1 ligation of Tie2 strengthens the interactions between 
endothelial and periendothelial supportive cells; whereas Ang2 primarily disrupts these interactions 
resulting in vessel destabilization [280]. The final effect of Ang2 will then depend on the presence of 
other angioregulatory cytokines, the effect being either an angiogenic response or vessel regression 
(Table 18). 
 
Table 18. The Ang/Tie2 system in angiogenesis. 
 Main source Receptor Tie2 effect Main effect on endothelial cells 
 
Ang1 
 
Non-endothelial cells 
AML cells 
 
Tie1 
Tie2 
 
Agonist 
 
Stabilizing and maturation of 
neovasculature 
Important for cell-cell interaction 
Antiapoptotic effect 
 
 
Ang2 
 
Endothelial cells 
AML cells 
 
Tie2 
 
Partial 
agonist/ 
antagonist 
 
Context-dependent effects 
Destabilizing and regression of 
neovasculature 
Angiogenic response in the presence of 
VEGF or absence of Ang1 
 
   
   Several studies suggest that the Ang/Tie2 system is important both for leukemogenesis and 
chemosensitivity in AML [231, 281], and these effects may then be mediated through a bidirectional 
crosstalk between AML cells with constitutive Ang release and their neighboring endothelial cells. 
However, the effect of Ang/Tie2, and especially Ang2 expression, in leukemogenesis and on 
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chemosensitivity is still controversial. High pretreatment levels of Ang2, investigated both by mRNA 
expression levels in peripheral blood mononuclear cells [281], and by semi quantitative 
immunohistochemistry in bone marrow biopsies [282], have been associated with chemosensitivity 
and favorable outcome [281, 282]. In contrast, high levels of Ang2 in bone marrow blast detected by 
real time polymerase chain reaction (PCR) [283], or high plasma levels of  Ang2 [284], have also been 
associated with an unfavorable prognosis [283, 284]. The latest is also in concordance with a study 
demonstrating that high levels of circulating Ang2 were associated with an unfavorable outcome after 
allo-SCT among AML or high risk MDS patients [285]. Taken together, these conflicting results 
demonstrated that both the origin of Ang2, e.g. leukemic cells or stromal cells [230], and the context, 
e.g. agonistic/antagonistic interactions in the presence of Ang1 and other cytokines [279], probably 
also is clinical relevant.  
   Therapeutic targeting of the Ang/Tie2 system is possible by administration of selective Ang1/2-
neutralizing or Tie2 blocking antibodies [230]. In experimental models this strategy decreases 
endothelial cell proliferation and thereby inhibits angiogenesis, causes tumor necrosis and reduces 
tumor growth [230, 286]. Ang1/2 neutralization can also inhibit angiogenesis driven by other 
proangiogenic cytokines [287], e.g. the VEGF-dependent angiogenesis that seems to have a 
prognostic impact in AML [288]. Furthermore, experimental studies suggest that combined 
antiangiogenic targeting is more effective than targeting VEGF alone [289]. Both VEGF and Ang2 
have prognostic impact in AML [231, 289], and combined targeting is then of particular interest [290].  
 
MMPs 
   MMP expression is upregulated in several malignancies, including AML. These proteases were 
originally thought to be responsible for degradation and turnover of the extracellular matrix, but they 
are in addition involved in angiogenesis, inflammation and cell migration [101]. The MMPs are strictly 
regulated by their endogenous inhibitors called Tissue Inhibitor of MMPs (TIMPs). The TIMPs are 
broad-spectrum inhibitors of MMPs, although there are some differences in their affinities for various 
MMPs. An imbalance between MMPs and TIMPs is believed to promote AML progression [101]. 
Importantly, the TIMP molecules should not only be regarded as MMP antagonists; they have complex 
functions and both growth-enhancing and antiapoptotic effects have been described [291]. A total of 
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23 different human MMPs and four different TIMPS have been identified; those that are important in 
AML are summarized in Table 19.    
 
Table 19. MMPs and TIMPs in AML (expression frequencies according to [189]). 
Name AML expression Characteristics 
 
Refs 
 
MMP-2 
 
49% 
 
Both secreted and membrane bound in AML cells, up 
regulation is associated with drug resistance and adverse 
prognostic outcome in AML 
 
[189, 292-
295] 
 
MMP-7 
 
21% 
 
Can generate soluble FasLigand which further increases 
apoptosis in surrounding cells through the activation of Fas 
receptor. Associated with resistance to chemotherapeutics 
 
[296] 
 
MMP-9 
 
47% 
 
Both secreted and membrane bound in AML cells, higher 
expressed in more mature AML (FAB M4/M5) and 
associated with an invasive phenotype 
 
[189, 295, 
297, 298] 
 
MMP-10 
 
100% 
 
Demonstrated to induce growth both in lymphoma and solid 
tumors 
 
[299] 
    
 
TIMP-1 
 
60% 
 
Antiapoptotic effects in malignant cells, including malignant 
hematopoietic cells. 
 
[291] 
 
TIMP-2 
 
94% 
 
Growth-regulatory effects through specific binding to 
intergrins 
 
 
[291] 
 
   MMPs are considered promising targets for cancer therapy. Several MMP inhibitors (MMPIs) have 
been devoloped and can be broadly divided into peptidomimetic, non-peptidomimetic, tetracycline 
derivatives and naturally occurring inhibitors (Table 20). The results from testing in animal models and 
in cell cultures were compelling, including studies in AML cell lines [300]. These results generate a 
great expectation [301, 302]. However, results from clinical trials have been disappointing with several 
studies demonstrating none or only marginal effects [301, 302]. The reasons for these failures are 
assumed to be multifactorial. Firstly, results from animal models may not predict the outcome for 
human tumors [303]. Secondarily, most clinical studied were performed in advanced tumors, while 
MMPIs may be more effective in the early stages due to their cytostatic rather than cytotoxic effect 
[303]. Thirdly, the MMPIs used in clinical studies target a broad spectrum of MMPs, and improved 
target specificity may be more beneficial [303]. Finally, MMPs and TIMPs may have protective roles in 
certain cancers [304].    
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   Although no MMPIs have been ivestigated in clinical trials for AML, MMPs still represent an potential 
interesting therapeutic target in these patients [101]. However, a better understanding of the role of 
different MMPs in leukemogenesis is needed before optimal clinical studies can be designed. 
 
Table 20. Classification, nomenclature and pharmacological characteristics for MMP inhibitors 
used in clinical trials [101]. 
Classification Central inhibitors Characteristics 
Peptidomimetic Marimastat / BB-2516 
Batimastat / BB-94 
ABT-518 
 
Low water solubility and/or bioavailability. 
Not for further clinical development. 
 
Non-
peptidomimetic 
Prinomastat / AG3340 
Tanomastat / BAY12-9566 
BMS-275291 
CGS27023A / MMI270 
Good oral bioavailability. 
Musculoskeletal symptoms are the main side 
effects. 
Tetracycline 
derivates 
 
Metastat/COL-3/ 
SC-683551 
Good oral bioavailability. 
Main side effects include malaise and 
photosensitivity. 
Naturally 
occurring 
inhibitors 
Neovastat/AE-941 Good oral bioavailability. 
An additional effect is inhibition of VEGF and 
induction of apoptosis in endothelial cells. 
 
 
 
Endocan 
   Endocan, previously called endothelial cell specific molecule-1, is a soluble proteoglycan with a 
molecular weight of 50 kDa [305]. Experimental evidence suggests that endocan act as a key player in 
the regulation of cell adhesion, local inflammation and tumor progression. Endocan serum levels are 
elevated in patients with various malignancies [306], and in patients with severe sepsis [306]. Endocan 
is produced by endothelial cells but not by AML cells [265]. Pro-angiogenic growth factors (e.g. VEGF 
and HGF) increase endocan expression by human endothelial cells [305], whereas Ang2 seems to 
have an opposite effect [230]. The possible role of endocan in leukemogenesis and its possible use as 
a biomarker in human AML require further studies [305]. 
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AIMS OF THE THESIS 
   AML is a heterogenic disease and the response to chemotherapy differs between patients. The AML 
genotype is an important prognostic parameter in AML. Chromosomal abnormalities, gene mutations 
and gene expression abnormalities all affect critical protein levels and functions in primary human AML 
cells and may exert profound effects on chemosensitivity. Pharmacological targeting of these protein 
abnormalities has emerged as a possible therapeutic strategy in human malignancies, including AML. 
However, given the heterogeneity of AML one would expect differences between patients in their 
responses to such targeted therapies. Furthermore, the interactions between the AML cells and their 
neighboring bone marrow stromal elements are important in leukemogenesis and will probably also be 
important for chemosensitivity. Bone marrow angiogenesis with increased MVD is observed in human 
AML, and the endothelial cells will then be important both for the supply of nutritients to the leukemic 
cells and as directly leukemia-supporting stromal cells.  
 
In this context the aims of this thesis were: 
x characterization of intracellular and extracellular signaling events that affect primary human 
AML cell proliferation, viability and constitutive release of angioregulatory cytokines; 
x based on the studies described above, to describe the biological heterogeneity in human AML; 
x to investigate how pharmacological targeting of intracellular molecules (HSP90, NF-țB, the 
PI3K-mTOR pathway) and Tie-2 receptor signaling affects the functional characteristics of  
primary human AML; 
x to investigate differences in systemic cytokine levels, including hematopoietic growth factors 
and angioregulatory cytokines, between acute leukemia patients after they have achieved 
complete hematological remission. 
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MATERIAL AND METHODOLOGICAL CONSIDERATIONS 
 
 
PREPARATION AND CULTURE OF PRIMARY HUMAN AML CELLS 
 
   By definition the bone marrow of AML patients contains at least 20% leukemic blasts [11]. In our 
studies we used AML blast derived from peripheral blood, and we then selected patients with high 
peripheral blood blast counts so that enriched AML cell populations could be prepared by density 
gradient separation alone [307]. Thus, our results may be representative only for this subset of 
patients. This methodological approach was used because the AML cell populations then contained 
95% AML cells, and more extensive separation procedures can alter gen expression and/or the 
constitutive release for soluble mediators [307]. Cells were stored in liquid nitrogen until used. The 
advantages of this approach are the possibility to use well-characterized AML cells, additional 
experiment are possible for the same patient and it is possible to study larger patient populations 
within reasonable time.  
   Addition of serum to cultures represents a non-standardized factor and in general our experiments 
were performed in serum-free medium. However, serum supplementation is often necessary when 
culturing non-myeloid cell, e.g. in stromal cell experiments and coculture experiments [266, 270].  
   Spontaneous apoptosis will always occur during in vitro culture of AML cells [307]. The fraction of 
cell that stays viable during culture varies between patients [230]. Thus, the effect of pharmacological 
intervention always occurs in the context of ongoing spontaneous apoptosis as can be seen from the 
control cultures that were included in all experiments.  
   Several cytokines can function as growth factors in AML [307]. The optimal cytokine combination for 
AML cell proliferation varies between patients [307]. In our studies of cytokine dependent proliferation 
we usually added FLT3-L, SCF and GM-CSF. Although detectable proliferation is not observed in all 
patients, a majority of AML blasts will proliferative in the presence of these cytokines [36]. 
   In our studies we usually included consecutive or unselected patients diagnosed with AML at our 
hospital. As discussed in detail previously [36], our patients are probably representative for the general 
AML patient population with regard to clinically relevant characteristics (i.e. prognosis). The patient 
age is relatively high, in contrast to many clinical studies that mainly include younger patients, e.g. 
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<60-65 years of age. Such clinical studies are not representative for the AML patient population as a 
whole. The disadvantages are that our patients are heterogeneous with regard to treatment and 
survival analyses are therefore difficult, and our populations included an expected low number of 
patients with good-prognosis genetic abnormalities.  
 
Table 21. Comparison between AML patients included in article III and a general AML 
population. The table compares age/gender and biological AML cell characteristics [1, 11, 16, 308].  
Demographic data 
and disease history  Study paper III 
General AML 
population 
 
Gender  
 
 
Male/female 
 
53%/47% 
 
60%/40% 
Age  (median) 
 
Years 64 70 (often lower in 
clinical trials) 
AML cell 
differentiation 
 
   
FAB classification  M0-1 41% 20-25% 
 M2 21% 25-30% 
 M3 0% 5-10% 
 M4-5 38% 35-40% 
 M6 0% 3-5% 
 M7 0% 3-5% 
 
 
   
Genetic 
abnormalities 
 
   
Cytogenetic Favorable 5% 15-20% 
 Unfavorable 28% 15-20% 
 Intermediate 8% 10-15% 
 Normal 58% 45% 
    
FLT3 ITD 41% 25-30% 
 TKD 3% 5% 
    
NPM1 
 
Mutated 31% 30-35% 
 
 
   We did not included patients with APL (FAB-M3), and the uncommon erythroleukemia (FAB-M6) and 
megakaryocytic leukemia (FAB-M7) were not detected among our patients. We also have few patient 
with favorable cytogenetic, e.g. t(8;21), inv(16)/t(16;16). These abnormalities are uncommon in older 
patients and these patients often have lower peripheral blood blast counts, the low frequency is 
therefore expected [309].  
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SYSTEM BIOLOGY AND BIOINFORMATICS APPROACHES 
   The term system biology has been widely used in a variety of contexts the last decade. The term 
describe a biology based inter disciplinary study field that focuses on complex interactions in biological 
system, trying to use a holistic instead of a reduction perspective [310]. System biology can be divided 
into minor groups where the most important are given in Table 22. 
 
Table 22. System biology approaches in AML. The table lists the most common system biology 
approaches together with their main characteristics and key references for the use in AML are given. 
 
Approaches Characteristics AML examples 
 
Genomics 
 
 
DNA sequencing 
 
[43] 
Transriptomics Global gene expression profiling by DNA 
microarray analyses 
 
[20, 21] 
Interferomics Studying of transcription correcting factors, i.e. 
micro RNA 
 
[311, 312] 
Epigenomics Epigenetic regulation of transcription, e.g.  DNA 
methylation and histone acetylation 
 
[313, 314] 
Proteomics Proteomics is large-scale study of proteins or 
peptides, particularly their expressions, structures 
and functions 
 
[315] 
Phosphoproteomics A branch of proteomic that identifies, classifies, 
and characterizes protein phosphorylation 
 
[198] 
Metabolimics Characterization of cell metabolism  [316] 
 
System biology requires several graphical and staticall methods that will be further discuss. Cluster 
analysis is the assignment of a set of observations into subsets (referred to as clusters), observations 
in the same cluster then show similarities [317]. There are different types of clustering that can be 
used. Hierarchical clustering is a method that seeks to build a hierarchy, e.g. groups, of clusters. The 
algorithms begin with each element as a group and merge them into successively larger clusters. An 
important step clustering analysis is to select a distance measure, which will determine how the 
similarity of two elements is calculated. There are different methods to calculate this distance that can 
influence the results from the clustering, although the differences between methods are in general 
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small [317]. A more simplified method to describe correlations between different patients and 
mediators present this as correlation maps, this approach can give an overview regarding association 
of different samples [189].  
   Hierarchical clustering creates groups of clusters which often are presented in a tree structure called 
a denogram. The root of the tree consists of a single cluster containing all observations, and the 
leaves correspond to individual observations. Algorithms for hierarchical clustering are generally 
agglomerative, in which one starts at the leaves and successively joins samples or subclusters 
together [317]. The hierarchical cluster analysis can be performed by unsupervised or supervised 
analysis. In the first one the results of experiments do not take external factors such as clinical or 
biological features into account. In contrast, a supervised clustering can take these parameters into 
account in the final analysis [20].  
   Interpretation of data obtained by unsupervised hierarchical cluster analysis is frequently performed 
by visualization as heatmaps. A heatmap is a graphical presentation of data where the values taken 
by a variable in a two-dimensional map are represented as colors [317]. The mosaic of a heatmap 
illustrates expression level by color intensities. Heatmap is often combined with hierarchal clustering 
where the rows and columns of the heatmap are organized based on results from the hierarchal 
clustering. Heat maps originated in two dimension displays of the values in a data matrix, low or high 
values are often given the most intense colors.  
   Hierarchical clustering and heatmaps are often followed by a hierarchal clustering with distance 
matrix, e.g. pairwise correlation between samples using Parson’s Correlation [20]. This gives a 
visualization of the similarities/differences between samples. The strongest colors, e.g. deep red or 
deep green, represent one hundred percent negative or positive correlation. A hundred percent 
positive correlation between two samples indicates that high expression level in one sample is always 
followed by high expression in the corresponding sample and vise versa [20]. 
   The advantages in the use this approach in AML is to visualize heterogeneity between individual 
patients [310]. In our experiments we have used this approach to classify effects of pharmacological 
targeting; this approach will then have the potential to define patient subgroups with regard to 
pharmacological effects. 
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SUMMARY OF THE RESULTS 
Paper I 
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their 
inhibitors: release profile and pharmacological modulation. 
Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud Ø.  
European Journal of Haematology 2010 Mar; 84(3): 239-251 
 
Background: Angiogenesis seems important both for leukemogenesis and chemosensitivity in AML. 
Angiogenesis is regulated by the balance between pro- and antiangiogenic cytokines and probably 
also by MMPs and their natural inhibitors, TIMPs, in angiogenesis. We investigated the constitutive 
release of MMPs and TIMPs for a large group of consecutive AML patients.  
Material and methods: AML cells were cultured in vitro either alone or together with microvascular 
endothelial cells, and the levels of MMPs and TIMPs were determined in culture supernatants. The 
effects of various emerging pharmacological agents on this release were evaluated.  
Results: AML cells showed constitutive release of several MMPs and TIMPs. For all patients 
detectable MMP-10 release was observed, and most patients showed detectable release of at least 
one additional MMP, usually MMP-9 or MMP-2. A significant correlation was found between MMP-9 
and TIMP-1 release and the release of several CCL and CXCL chemokines. MMP-9 release was 
higher for AML cells with monocytic differentiation corresponding to the FAB-subtype M4/M5 AML; it 
was mainly released in its inactive form, but endogenous active MMP-9 could be detected even in the 
presence of the constitutively released TIMP-1/2. Endothelial cells released relatively high levels of 
MMP-10, and these levels were further increased by coculture with AML cells. Heterogeneous 
responses to different pharmacological agents were observed. Patients achieving complete 
hematological remission after only one induction cycle often had undetectable MMP-2 levels, 
indicating a prognostic role of this MMP in AML. 
Conclusion: Primary human AML cells show constitutive release of both MMPs and TIMPs, and this 
release may be important for leukemogenesis and possibly also for chemosensitivity.
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Paper II 
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and 
endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive 
agonistic Ang-1 release.  
Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud Ø. 
Expert Opin Investig Drugs 2010 Feb; 19(2): 169-183. 
Background: The Tie-2 receptor can bind its agonistic ligand Ang-1 and the potential antagonist Ang-
2. Tie-2 can be expressed both by primary human AML cells and endothelial cells, and Tie-2-blocking 
antibodies are now being evaluated in clinical trials for cancer treatment.  
 
Material and methods: We investigated the effects of Tie-2-blocking antibodies, exogenous Ang-2 
and pharmacological targeting of various intracellular signaling pathways on AML cell proliferation and 
the constitutive release of angioregulatory mediators.  
 
Results: Tie-2-blocking antibodies had a growth inhibitory effect on human AML cells cocultured with 
microvascular endothelial cells, but this inhibition was not observed when leukemic cells were 
cocultured with fibroblasts or osteoblasts. AML cell viability in cocultures was not altered by anti-Tie-2. 
Furthermore, anti-Tie-2 decreased HGF levels and increased CXCL8 levels in cocultures, whereas the 
levels of endocan (a proteoglycan released by endothelial cells) were not altered. The only significant 
effects of exogenous Ang-2 were decreased levels of HGF and endocan. Constitutive AML cell 
release of agonistic Ang-1 was decreased by the proteasomal inhibitor bortezomib and the specific 
INB-kinase/NFNB inhibitor BMS-345541.  
 
Conclusion: Various strategies for modulation of Tie-2 mediated signaling should be considered in 
AML therapy, possibly in combination with other antiangiogenic strategies. 
 
 
 
 
61
 
Paper III 
Heat shock proteins expression profile for AML patients revels a distinct signature strongly 
associated with FLT3 mutation status - consequences and potentials for pharmacological 
intervention  
Reikvam H, Ersvær E, Skavalnd J, Hovland R, Petersen K, Hatfield K, Bruserud Ø. 
British Journal of Haematology 2012 Feb; 156(4): 468-80 
Background: HSPs act as molecular chaperones that prevent the formation protein aggregates and 
assist proteins in their folding to native structures. Malignant cells can express different HSPs and use 
them to avoid cellular differentiation and apoptosis. Therefore HSPs have emerged as therapeutic 
targets, and special inhibition of HSP90 chaperoning activity seems to be a promising approach. The 
aim of the study was to compare HSP levels for a large cohort of AML patients, and to investigate the 
effect of the HSP90 inhibitor 17-DMAG. 
Material and methods: Primary human AML cells derived from 75 consecutive patients were lysated 
and intracellular HSP levels measured. We used standardized bioinformatical tools to subclassify 
patients based on their HSP expression. Furthermore we also investigate the in vitro effect of HSP90 
inhibition on proliferation, apoptosis and angioregulators of primary human AML cells. 
Results: Intracellular expression of HSP27, HSP40, HSP60, HSP70 and HSP90Į were detected for 
all patients. Hierarchical clustering identified two major subsets, broadly divided into low and high 
expression of HSPs. HSP70 and HSP90 levels showed a strong correlation demonstrating a highly 
coordinated expression. Patients harboring FLT3 mutations generally showed high HSP levels, 
indicating a strong dependence of especially HSP90 in stabilizing oncogenic mutated FLT3. HSP90 
inhibition had a stronger proapoptotic effect in FLT3-ITD positive patients. Furthermore, HSP90 
inhibition had a strong antiproliferative and antiangiogenic effect regardless of other patient 
characteristics.  
Conclusions: HSP expression levels can be used to subclassify AMP patients, and the levels seem 
to depend on FLT3 mutation status. HSP90 inhibition has antiproliferative, antiangiogenic and 
proapoptotic effect, the later is especially strong in patients harboring FLT3-ITD mutations. This study 
supports the further investigation of HSP90 inhibitors in preclinical and clinical AML studies. 
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Paper IV: 
Angiogenic signature for AML patients and the possible effects of different pharmacological 
agents acting on the PI3K-mTOR pathway 
Reikvam H, Hatfield K, Tamburini J, Poulain J, Ersvær E, Ryningen A, Bruserud Ø. 
Manuscript 
Background: AML is a heterogeneous hematologic malignancy, with an overall AML-free survival of 
only 40-50% even after intensive therapy. Angiogenesis seems important both for leukemogenesis 
and chemosensitivity in AML and has emerged as a potential therapeutic target. It is regulated by the 
balance between pro- and antiangiogenic factors. The aims of the study were to investigate the effect 
on primary human AML cells of new therapeutic agents targeting the mTOR and the PI3K pathways, 
and especially the effects on angioregulatory mechanisms. 
Material and methods: AML cells were cultured under highly standard in vitro condition, and different 
pharmacological effects on proliferation, apoptosis and cytokine release were evaluated. 
Bioinformatical tools were used to subclassify patients according to the effects of the different agents.  
Results: The effect of two mTOR inhibitors (rapamycin and temsirolimus), and two PI3K inhibitors 
(GDC-0941 and 3-methyladenin (3-MA)) were evaluated. All agents showed a general antiproliferative 
effect but only modest proapoptotic effect, demonstrating a cytostatic rather than a cytotoxic effect. 
The effects on proliferation varied considerably among patients, but all four drugs often had similar 
effects in the same patient. From the constitutive release profile of angiogenic factors we where able 
to identified two major subset based on the clustering of angioregulatory mediators, and further two 
major patient clusters. The effect of the agents differed between patients, but the drugs often had 
similar effects on the various angioregulatory mediators in the same patients. 
Conclusion: Pharmacological targeting of the intracellular signaling pathway PI3K-mTOR has direct 
antileukemic effects for most patients, but for a minimal subset the proliferation is increased. The 
drugs may also have indirect antileukemic effects through altered regulation of bone marrow 
angiogenesis. 
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Paper V: 
The pretransplant serum cytokine profile in allogeneic stem cell recipients differ from healthy 
individuals and different profiles are associated with different risk of posttransplant 
complications 
Reikvam H, Mosevoll KA, Melve G, Günther CC, Sjo M, Bentsen PT, Bruserud Ø 
Biol Blood Marrow Transplant 2012 Feb; 18(2): 190-9.
 
Background: Cytokines play a key role in regulation of normal and malignant hematopoiesis, 
angiogenesis and inflammation. Serum levels of several cytokines are altered in patients with 
hematologic malignancies, and certain pretransplant cytokine levels may have a prognostic impact in 
patients treated with allogeneic stem cell transplantation (allo-SCT). However, the cytokine system 
constitutes an interacting functional network, and it may therefore be more relevant examine at serum 
cytokine profiles rather than the serum levels of single cytokines in allotransplanted patients. 
Material and methods: We therefore investigated the pretransplant serum levels of 35 cytokines in a 
group of 44 consecutive allo-SCT patients, mainly with a primary diagnosis of acute leukemia. Serum 
samples were collected before start of myeloablative conditioning therapy when all patients were in 
complete hematological remission. Bioinformatic approaches were used to identify patient 
groups/subsets.  
Results: Unsupervised hierarchical clustering analysis identified three major patient groups/subsets. 
These groups differed especially in the levels of hepatocyte growth factor (HGF) and granulocyte-
colony-stimulating factor (G-CSF), and one of the groups was characterized by low early treatment-
related morbidity and high levels of HGF and G-CSF. The degree of weight gain/fluid retention after 
conditioning therapy did not differ between the patient subsets, but fluid retention showed a significant 
correlation with pretransplant serum levels of basic Fibroblast growth factor (bFGF).  
Conclusion: We conclude that the pretransplant serum cytokine profile shows a considerable 
variation even between patients in complete hematological remission. These differences are clinically 
relevant in allo-SCT recipients, and they may also be relevant for patients who can not receive allo-
SCT and instead receive consolidation or maintenance treatment with new target therapy. 
 
 
64
GENERAL DISCUSSION 
 
AML HETEROGENEITY 
 
   Cytogenetic analysis allows a prognostic subclassification of patients receiving intensive 
chemotherapy for non-APL variants of AML [19]. Distinct mutations involved in leukemogenesis have 
additional prognostic impact, e.g. patients with FLT3-ITD have an adverse prognosis whereas patients 
with NPM1 mutation have a good prognosis in the absence of FLT3-ITD [15]. Global gene expression 
profiling in AML has revealed that major prognostic subgroups based on these genetic markers are 
recapitulated in global gene expression patterns and have identified specific signatures for patients 
with distinct cytogenetic abnormalities and gene mutations [20, 21, 318]; their prediction can then be 
made with almost 100% specificity and sensitivity [319].  
   DNA methylation and histone modulation are important epigenetic mechanisms involved in 
leukemogenesis, and different cytogenetic subgroups are characterized by distinct epigenetic patterns 
[313, 314, 320]. However, clustering based on methylation patterns seems less pronounced than the 
gene expression profiles [313]. It has in addition been demonstrated that AML patient subsets express 
specific signatures of microRNA, i.e. a class of small noncoding RNAs involved in regulation of 
protein-encoding mRNA [311, 312].  
In our present studies the majority of patients were characterized by cytogenetic analyses and in 
addition analysis of FLT3 and NPM1 mutations. Cytogenetic analyses were not available for a subset 
of patients. For some patients no mitosis were available for culture for chromosomal analyses, for 
other patients the samples for cytogenetic analyses were not collected at the time of diagnosis and we 
did not performed cytogenetic analyses on cryopreserved  cells because previous reports suggest that 
these results will be unreliable [321]. 
 
“ONE SIZE FITS ALL” – AML THERAPY REVISITED 
 
   The standard induction regimen in AML has for many years been an antracycline plus cytarabine, 
and this is followed by repetitive cycles of intensive consolidation therapy usually including high-dose 
cytarabine. This treatment is curative for most patients with favorable and for a large subset of patients 
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with intermediate risk disease, but only for a small minority with unfavorable risk profile. Knowing the 
biological heterogeneity of AML, an important question is now whether one still should recommend the 
same treatment to all patients. However, the most important improvements in AML therapy during the 
last two decades have not been the introduction of new therapeutic agents, but rather a more optimal 
use of well-known antileukemic drugs combined with a better supportive care [85]. Further studies 
based on specific targeted therapy will hopefully improve patient survival, even though the results from 
clinical studies of gemetuzumab ozogamacin [322], FLT3 inhibitors [323], farnesyltransferase inhibitors 
[324], histone deactylase (HDAC)-inhibitors [325] and bortezomib [326] so far have been rather 
disappointing. Our present experimental observations in article III suggest that therapeutic targeting of 
HSP90 will be most effective in FLT3-ITD patients, wears based on observations in article IV indicate 
that targeting of PI3K-mTOR may be less effective in a minority of patients 
CURATIVE VERSUS DISEASE STABILIZING AML-THERAPY 
 
   The overall AML relapse risk after conventional therapy is still 40-50% for younger patients [85], and 
the large group of patients above >65-70 years of age has an inferior prognosis [327] due to (i) patient 
related factors like general comorbidity, low performance status and unacceptable toxicity when using 
high-dose cytarabine [309]; and (ii) disease-related factors with a high frequency of high-risk 
cytogenetics and secondary AML [327]. The therapeutic decisions in elderly patients should be 
individualized and be based on the possibility to achieve complete remission versus the risk of 
treatment-related morbidity or mortality [309]. Combination of ATRA, valproic acid or another HDAC-
inhibitors and eventually theophylline or low-toxicity chemotherapy may be an alternative with low 
toxicity, and this treatment can induce disease stabilization for a subset of patients but only for a 
limited time [328-330]. The pharmacological agents investigated in the present thesis would therefore 
be considered for (i) combination with induction and/or consolidation therapy to increase AML-free 
survival; (ii) to be used alone or in combination with other drugs of palliative or disease stabilizing 
therapy; or (iii) as maintenance therapy in patients in complete hematological remission to eradicate 
residual disease and thereby decrease the relapse risk. Maintenance therapy is not common in AML, 
but results from recent studies suggest that this strategy may be effective and reduce the relapse risk 
[331, 332]. 
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ANTIANGIOGENIC THERAPY IN HUMAN AML 
 
The biological and clinical background for antiangiogenic therapy 
   Several antiangiogenic agents have a relatively low toxicity compared with conventional 
chemotherapy and are used for disease stabilization in other malignancies [244]. Crosstalk between 
AML cells and neighboring cells is probably important for cancer cell survival and proliferation, as well 
as for disease progression and chemosensitivity [265, 266]. Firstly, the bone marrow MVD can be 
evaluated either in biopsies [333], or by magnetic resonance examination, indicating that high density 
is associated with shorter overall and AML-free survival [267]. Secondly, a semiquantitative 
examination of specific angioregulators can be done by histochemistry of bone marrow biopsies, and 
high Ang2 levels then have a prognostic impact [281]. Secondly, high levels of intracellular or serum 
angiogenic factors are also associated with an adverse prognosis [284, 288, 294]. Finally, in vitro 
studies have demonstrated that the cytokine crosstalk between leukemic and endothelial cells can 
increase AML cell growth [189, 231]. These observations support the hypothesis that angiogenesis 
and endothelial cells are important for AML cell proliferation, survival and chemosensitivity. 
 
Direct targeting of angiogenic factors 
   VEGF is probably the best characterized target for antiangiogenic therapy. Bevacizumab is a 
recombinant monoclonal antibody specific for VEGF-A. In two studies bevacizumab was administered 
to patients with refractory AML and resulted in modest clinical benefit [334, 335]. Suntinib is a VEGF 
RTK inhibitor that in addition inhibits KIT and FLT3 initiated signaling, and based on the available 
results in AML the drug seems to have a limited clinical effect with complete or partial remissions of 
only short duration for a subgroup of patients [336, 337]. HGF/MET inhibitors [273] and targeting of the 
Ang/Tie2 system [338] have not yet been investigated in human AML. MMPs were previously 
considered as possible targets in antiangiogenic therapy [101]; they have not been evaluated in 
hematological malignancies, but results from initial clinical studies in solid tumors have been 
disappointing [101]. Thus, antiangiogenic therapy alone seems to have limited anticancer or 
antileukemic effects, however the clinical use of these strategies should be further evaluated. The 
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results from the present thesis clearly suggest that targeting of angioregulatory mechanisms is a part 
of the antileukemic effect of several targeted therapies that now are considered for AML therapy. 
Targeting of endothelial cells - vascular disrupting agents 
   An alternative approach is to destabilize the cancer-induced microvessel network through selective 
targeting of proliferating endothelial cells  [339]. Vascular disrupting agents (VDAs) are a new class of 
agents that target blood vessels by direct binding to microtubules in endothelial cells. The main goals 
for VDAs are to generate a rapid and selective vascular shutdown in the malign microenvironment and 
thereby induce secondary cancer cell death due to ischemia [339]. The effects of VDAs have not yet 
been completely elucidated, but probably involve inhibitory effects of the tubulin skeleton [339]. The 
question of possible systemic toxicity due to general endothelial cell damage or endothelial dysfunction 
has not been completely answered [290]. The best studied of these drugs is fosbretabulin/CA4P [339], 
and this drug and its analogue OXi4503 have shown promising preclinical results [264, 340] 
 
Inhibition of angiogenesis through targeting of intracellular signaling pathways  
   An alternative strategy is to target intracellular signaling pathways and thereby inhibit malignant cells 
as well as the stromal cells, including endothelial cells [244]. Although we do not have detailed 
knowledge about the molecular mechanism of thalidomide, lenaladomide and bortezomib, these drugs 
seem to inhibit angiogenesis possibly through NF-țB inhibition when used for the treatment of MM 
[121]. Similar effects may also be seen in AML.  
   HSP90 inhibition probably targets multiple proangiogenic regulators and may thus have direct 
inhibitory effects on leukemic cells and in addition have indirect antileukemic effects through inhibition 
of angiogenesis by targeting a wide range of client proteins [175, 341]. Firstly, one important pathway 
that is usually upregulated during angiogenesis is the HIF/VEGF signaling axis [342]. Several key 
mediators of this pathway, including the HIF and VEGF receptor, are HSP90 client proteins [341]. 
Secondly, HSP90 is also important for stabilization of AKT; this kinase mediates phosphorylation and 
activation of NO synthase (NOS) that is important for stimulation and activation of endothelial cells 
[341]. Thirdly, HSP90 inhibition can reduce the constitutive release of several angiogenic factors by 
AML cells [175]. Finally, the HSP90 inhibitor SNX-2112 suppresses capillary tube formation in human 
umbilical vein endothelial cells through inhibition of the AKT/NOS pathway [222]. Clinical trials of 
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HSP90 inhibitors in AML are in progress [209] and it will then be important to evaluate both direct and 
indirect antileukemic effects [213]. 
   The PI3K-mTOR pathway also seems to have a crucial role in angiogenesis. PI3K activation and 
phosphorylation is probably important for activation of the VEGF receptor [343]. Furthermore, Ang1 
can phosphorylate and thereby activate Tie2 in a PI3K-dependent manner and thereby induce survival 
and migration of endothelial cells [343]. mTOR also seems to be important in angiogenesis, possibly 
by acting as a switch in endothelial cell metabolism that supports their proliferation [133]. mTOR 
inhibition thereby seems to have an antiangiogenic effect [344], which is also observed in AML [345]. 
 
Targeted therapy after remission induction – the possible importance of an altered cytokine 
network 
Targeted therapy to AML patients in complete hematological remission is now considered (see above), 
and our observation described in article V show that this treatment will be given in a specific biological 
context, i.e. an altered cytokine network. Our present results suggest that the pretherapy status of the 
cytokine network has an impact of the post therapy clinical course in allo-SCT patients. Future studies 
have to clarify whether the altered cytokine network also will influence the efficiency of the new target 
therapy, e.g. HSP90 and PI3K-mTOR targeting treatment.  
CONCLUDING REMARKS 
 
   New targeting therapies with antiangiogenic effects are currently considered in human AML. 
Although the clinical experience so far is limited, several of these therapies alone appear to have 
limited antileukemic effects. However, the scientific basis for simultaneous inhibition of several 
intracellular signaling systems in cancer treatment is emerging and this strategy may be more 
effective. Antiangiogenic effects may then be a part of such strategies. Given the heterogeneity of 
AML, further research is warranted to try to identify patient subsets that are likely to benefit from these 
approaches.  
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